

Evaluating Chemicals for Thyroid Disruption: Opportunities and Challenges with *in Vitro* Testing and Adverse Outcome Pathway Approaches

Pamela D. Noyes,¹ Katie Paul Friedman,² Patience Browne,³ Jonathan T. Haselman,⁴ Mary E. Gilbert,⁵ Michael W. Hornung,⁴ Stan Barone Jr.,⁶ Kevin M. Crofton,^{2†} Susan C. Laws,⁵ Tammy E. Stoker,⁵ Steven O. Simmons,² Joseph E. Tietge,⁴ and Sigmund J. Degitz⁴

¹National Center for Environmental Assessment, Office of Research and Development (ORD), U.S. Environmental Protection Agency (EPA), Washington, DC, USA

²National Center for Computational Toxicology, ORD, U.S. EPA, Research Triangle Park, North Carolina, USA

³Environment Health and Safety Division, Environment Directorate, Organisation for Economic Co-operation and Development (OECD), Paris, France

⁴Mid-Continent Ecology Division, National Health and Environmental Effects Research Laboratory (NHEERL), ORD, U.S. EPA, Duluth, Minnesota, USA

⁵Toxicity Assessment Division, NHEERL, ORD, U.S. EPA, Research Triangle Park, North Carolina, USA

⁶Office of Pollution Prevention and Toxics, Office of Chemical Safety and Pollution Prevention, U.S. EPA, Washington, DC, USA

BACKGROUND: Extensive clinical and experimental research documents the potential for chemical disruption of thyroid hormone (TH) signaling through multiple molecular targets. Perturbation of TH signaling can lead to abnormal brain development, cognitive impairments, and other adverse outcomes in humans and wildlife. To increase chemical safety screening efficiency and reduce vertebrate animal testing, *in vitro* assays that identify chemical interactions with molecular targets of the thyroid system have been developed and implemented.

OBJECTIVES: We present an adverse outcome pathway (AOP) network to link data derived from *in vitro* assays that measure chemical interactions with thyroid molecular targets to downstream events and adverse outcomes traditionally derived from *in vivo* testing. We examine the role of new *in vitro* technologies, in the context of the AOP network, in facilitating consideration of several important regulatory and biological challenges in characterizing chemicals that exert effects through a thyroid mechanism.

DISCUSSION: There is a substantial body of knowledge describing chemical effects on molecular and physiological regulation of TH signaling and associated adverse outcomes. Until recently, few alternative nonanimal assays were available to interrogate chemical effects on TH signaling. With the development of these new tools, screening large libraries of chemicals for interactions with molecular targets of the thyroid is now possible. Measuring early chemical interactions with targets in the thyroid pathway provides a means of linking adverse outcomes, which may be influenced by many biological processes, to a thyroid mechanism. However, the use of *in vitro* assays beyond chemical screening is complicated by continuing limits in our knowledge of TH signaling in important life stages and tissues, such as during fetal brain development. Nonetheless, the thyroid AOP network provides an ideal tool for defining causal linkages of a chemical exerting thyroid-dependent effects and identifying research needs to quantify these effects in support of regulatory decision making. <https://doi.org/10.1289/EHP5297>

Introduction

Regulatory programs within the U.S. Environmental Protection Agency (EPA) are responsible for protecting public health and the environment from the potential hazards and risks of chemical exposures. To quickly and economically predict chemical hazard, and reduce laboratory animal testing, the U.S. EPA and many other government institutions and stakeholders are placing an emphasis on designing, validating, and implementing alternative approaches to whole animal toxicity testing to support chemical safety assessments and risk-based decisions (ECHA 2016; ICCVAM 2018; National Academies of Sciences, Engineering, and Medicine 2007; U.S. EPA 2018). These alternative approaches, more recently termed new approach methodologies, may encompass any of a broad range of *in vitro* technologies [e.g., robotic-based higher-throughput screening (HTS), lower-throughput formats], omic approaches (e.g., microarray, RNA-sequencing, proteomics,

genome editing), and *in silico* modeling (e.g., molecular docking to model interactions of small molecules and proteins, computational read-across to predict the toxicity of data poor substances using data rich sources).

Coincident with the increasing availability of alternatives to traditional animal testing, government agencies have been seeking to adopt these new approach methodologies in chemical safety evaluations. The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and National Toxicology Program Center for the Evaluation of Alternative Toxicological Methods recently finalized strategies for establishing new approaches in chemical safety evaluations for U.S. federal agencies (ICCVAM 2018). The U.S. EPA has published plans to promote the use of nonanimal alternative test strategies under the amended Toxic Substances Control Act (TSCA) (U.S. EPA 2018). Likewise, the U.S. EPA's Endocrine Disruptor Screening Program (EDSP), which screens and tests chemicals for interference with estrogen, androgen, and thyroid hormone (TH) signaling, has been transitioning toward use of *in vitro* HTS to evaluate chemicals for endocrine activity (U.S. EPA 2015b, 2017). *In vitro* HTS has been implemented under the EDSP to screen chemicals for interaction with estrogen and androgen receptors (Browne et al. 2015; Judson et al. 2015, 2017; Kleinstreuer et al. 2017; U.S. EPA 2014), as well as steroidogenesis pathways (Botteri Principato et al. 2018; Haggard et al. 2018a; Karmaus et al. 2016). Several *in vitro* HTS assays for identification of thyroid active chemicals are now available, or under development, and the ToxCast and Tox21 programs have implemented *in vitro* HTS for targets in the thyroid pathway (Collins et al. 2008; Dix et al. 2007; Judson et al. 2010; Kavlock et al. 2008; Thomas et al. 2018). In Europe, the Joint Research Commission European Union Reference Laboratory for Alternatives to Animal Testing has been developing and validating *in vitro* thyroid assays for test guidelines

Address correspondence to Pamela Noyes, U.S. EPA, 1300 Pennsylvania Ave., N.W. (Mail Code 7203M), Washington, DC 20460 USA. Telephone: (202) 564-8122. Email: Noyes.pamela@epa.gov

†Retired.

The authors declare they have no actual or potential competing financial interests.

The views expressed in this manuscript are those of the authors and do not necessarily reflect the views or policies of the U.S. EPA or OECD.

Received 8 March 2019; Revised 1 July 2019; Accepted 13 August 2019; Published 5 September 2019.

Note to readers with disabilities: *EHP* strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in *EHP* articles may not conform to 508 standards due to the complexity of the information being presented. If you need assistance accessing journal content, please contact ehponline@niehs.nih.gov. Our staff will work with you to assess and meet your accessibility needs within 3 working days.

(EU Science Hub 2017), following an Organisation for Economic Co-operation and Development (OECD) scoping document on the availability of *in vitro* methods to investigate modulators of TH signaling (OECD 2014). Efforts to develop new methods for evaluating chemical interactions with the thyroid pathway have been informed by recent initiatives to evaluate the empirical evidence of chemical mechanisms of thyroid disruption (e.g., EU 2017; Murk et al. 2013).

To meet regulatory requirements for identifying potential endocrine disruptors, integration of a chemical's toxicity mechanisms and apical effects is needed. To date, this has been challenging for identifying chemicals that perturb TH signaling due to the limited availability of mechanistic and thyroid-relevant end points used to evaluate chemical safety. The OECD's recently updated Guidance Document 150 includes a revised conceptual framework and associated *in vitro* and *in vivo* test guidelines for evaluating endocrine disruption, including guidelines that have been updated to add thyroid end points (OECD 2018j). The European Chemicals Agency has adopted OECD Guidance Document 150 in its regulatory guidance for evaluating biocides and pesticides for endocrine disruption (Andersson et al. 2018).

Despite these recent advances, the application of new technologies to identify chemicals that exert effects through a thyroid mechanism continues to be complicated by a lack of linkages between chemical effects detected at macromolecular levels of biological organization (e.g., protein, cellular) and end points (e.g., serum TH) and adverse outcomes (e.g., developmental neurotoxicity) traditionally used in hazard assessment. Moreover, apical developmental end points collected in current regulatory test guidelines (Table 1) are not thyroid-specific and may occur through a variety of mechanisms, making it difficult to infer biological relevance, dose- and time-response relationships, and associated uncertainties. Taken together, regulatory test guidelines, when required for chemical assessments and regulatory decisions, continue to rely on thyroid measurements derived from *in vivo* animal testing with uncertainty about the mechanisms underlying adverse outcomes when observed.

Objectives and Overview of Challenges

To facilitate the regulatory application of data derived from these new technologies, we present an adverse outcome pathway (AOP) network (Figures 1–2) that links well-known and putative chemical targets of thyroid activity to downstream adverse outcomes. We examine current regulatory and scientific challenges in screening chemicals for thyroid-related perturbations, and propose how new *in vitro* technologies in the context of the thyroid AOP network can serve as a screening tool to identify chemicals that interact with targets in the thyroid pathway. Measuring chemical interactions with thyroid-related molecular targets can help elucidate whether adverse outcomes are mediated through a TH signaling mechanism.

TH signaling involves feedback interactions of the hypothalamic–pituitary–thyroid (HPT) axis, circulatory system, liver, and other tissues, collectively referred to here as the thyroid axis, that are critical to the maintenance of homeostasis and regulation of development and physiological functions (Bernal 2005; Denver 1998; Dussault and Ruel 1987; Oppenheimer and Schwartz 1997; Power et al. 2001; Silva 1995; Yen 2001; Zhang and Lazar 2000; Zoeller et al. 2005). In contrast to other endocrine pathways, evaluation of chemical impacts on the thyroid axis requires a more involved screening strategy because chemicals perturb TH signaling through several mechanisms other than the thyroid hormone receptor (TR) (Brucker-Davis 1998; Capen and Martin 1989; Capen 1997; DeVito et al. 1999; Hurley 1998; U.S. EPA 2015a). Clinical and experimental evidence describe

receptor-independent disruption of TH signaling that can result in reduced serum and tissue concentrations of TH that can lead to abnormal brain development, irreversible cognitive deficits, and other impairments, depending on the severity and timing of the TH insufficiency (as reviewed by Brucker-Davis 1998; Capen and Martin 1989; Crofton 2008; Diamanti-Kandarakis et al. 2009; Gilbert and Zoeller 2010; Gore et al. 2015; Hurley 1998; Körhle 2008; Murk et al. 2013; Zoeller 2005).

To help link molecular targets that may mediate thyroid-dependent apical effects, AOPs can be integrated in an AOP network (Figure 1) that includes multiple molecular initiating events (MIEs) sharing one or more key events (KEs) leading to one or more adverse outcomes (Ankley et al. 2010; Browne et al. 2017; Paul Friedman et al. 2016; Villeneuve et al. 2014; Villeneuve et al. 2018; Wittwehr et al. 2017). The thyroid AOP network herein (Figure 2) provides a tool for mapping TH signaling data collected at multiple levels of biological organization and using differing study designs. It is intended to aide in evidence integration and determining if a chemical is exerting an adverse outcome by a thyroid mechanism.

Discussion

In Vitro HTS Assays Aimed at MIEs in the Thyroid Axis

Over two dozen MIEs in the thyroid axis are demonstrated or hypothesized to be potential targets of chemicals (Table 2). These MIEs have been described at length in a recent review (OECD 2014) and workshop (Murk et al. 2013), so they will only be briefly summarized here. As a result of these and other collaborative efforts over the years, an increasing number of *in vitro* HTS assays and lower-/medium-throughput assays amenable to high-throughput platforms have been developed to measure chemical interactions with MIEs that may lead to perturbed TH synthesis, delivery, metabolism, and signaling. Perhaps two of the most well-characterized MIEs in the thyroid axis involve disruption of TH production by chemical interference with iodide uptake into thyroid follicular cells by inhibition of the Na⁺/I⁻ symporter (NIS) (Clewell et al. 2004; Lecat-Guillemet et al. 2008; Richards and Ingbar 1959; Tietge et al. 2005, 2010; Wolff 1998; Wu et al. 2016) and by inhibition of thyroperoxidase (TPO) activity (Coady et al. 2010; Davidson et al. 1978; Degitz et al. 2005; Francis and Rennert 1980; Tietge et al. 2010). An *in vitro* radioactive iodide uptake assay coupled to a human NIS-expressing HEK293T cell line has been developed and adapted for use as an *in vitro* HTS assay to identify chemicals that may inhibit iodide uptake by NIS (Hallinger et al. 2017; Wang et al. 2018). Another *in vitro* HTS assay has been developed to use the commercially available fluorescent peroxidase substrate, Amplex UltraRed to detect TPO inhibition (the “AUR-TPO” assay), and was used to screen approximately 1,000 chemicals in the ToxCast phase 1 and 2 libraries (Paul Friedman et al. 2016; Paul et al. 2014).

Extrathyroidal targets involved in chemical perturbations of TH metabolism and transport have also been the focus of *in vitro* HTS development. Some chemicals have been shown to inhibit the activity of iodothyronine deiodinase (DIO) enzymes in different species, tissues, and life stages (Butt et al. 2011; Capen and Martin 1989; Ferreira et al. 2002; Hood and Klaassen 2000; Morse et al. 1993; Noyes et al. 2011, 2013). The three DIO isoforms, Types I, II, and III (DIO1, DIO2, and DIO3, respectively) are differentially expressed and critical to the maintenance of TH in circulation and target tissues, such as brain (Dentice et al. 2013; Gereben et al. 2008; Körhle 1999; Salvatore et al. 1996; St Germain et al. 1994). A low-throughput colorimetric assay (Renko et al. 2012) has been adapted recently to 96-well plate

Table 1. U.S. EPA and OECD test guidelines with required (X) and optional (opt) *in vivo* thyroid end points and potentially thyroid-responsive adverse outcomes; laid out according to the adverse outcome pathway (AOP) diagram in Figure 1.

Test guideline	Study title	Life stage	TSH	T4	T3	Thyroid weight	Thyroid histopathology	Potential thyroid-responsive end points	Potential thyroid-responsive adverse outcomes	References
Mammalian (rat) models										
OCSPP 890.1450/ 890.1500	Pubertal development (EDSP Tier 1)	Peripubertal	X	X	—	X	X	—	—	U.S. EPA 2009
OCSPP 890.1400, OECD TG 441 ^a	Hershberger (EDSP Tier 1)	Castrated- peripubertal	—	opt	opt	—	—	—	—	OECD 2009; U.S. EPA 2009
OCSPP 870.3050, OECD TG 407	28-d oral toxicity ^{b,c}	Young adult	opt	opt	—	opt	X	—	—	OECD 2018g; U.S. EPA 2000a
OCSPP 870.3100, OECD TG 408	90-d oral toxicity ^{b,c}	Young adult	X	X	X	X	X	—	—	OECD 2018h; U.S. EPA 1998a
OCSPP non-guideline OCSPP 870.3700, OECD TG 414	CDT assay ^d Prenatal developmental toxicity ^c	Dam, offspring Dam, offspring	F0 (♀), F1 F0 (♀)	F0 (♀), F1 F0 (♀)	F0 (♀), F1 F0 (♀)	F0 (♀), F1 F0 (♀)	F0 (♀), F1 F0 (♀)	External, soft tissue, and skeletal malformations	Altered locomotor and sensory function- ing in offspring (OECD only)	U.S. EPA 2005 OECD 2018f; U.S. EPA 1998b
OCSPP 870.3650, OECD TG 421/422	Combined 28-d, repro/ developmental toxicity ^c	Parent, offspring	opt	F0 (♂), F1 & F0 (♀): “if relevant”	—	F0; opt, F1; X	F0; opt, F1; X	Gross developmen- tal malformations	Altered locomotor and sensory func- tioning in offspring (OECD only)	OECD 2018i; U.S. EPA 2000b
OCSPP 870.3800, OECD TG 443/416	EOGRT/two-gen reproduction ^c	Parent, offspring	F0, F1	—	F0, F1	—	—	Brain, CNS, and PNS histology and mor- phology, startle response habituation	Altered locomotor and sensory func- tioning in offspring (OECD only)	OECD 2018d; 2018k
OCSPP 870.6300, OECD TG 426	Developmental neurotoxicity	Parent, offspring	—	—	—	—	—	Brain, CNS, PNS his- tology and morphol- ogy, startle response habituation, learning, and memory	Altered locomotor, sensory, and cogni- tive functioning in offspring	OECD 2018c; U.S. EPA 1998c
OCSPP 870.4100- 4300, OECD TG 451- 453	Chronic toxicity/ carcinogenicity	Young adult	—	—	—	X	X	Thyroid gland hyper- trophy and hyperplasia	Thyroid tumors (rodent)	OECD 2018b; U.S. EPA 1998d
Non-mammalian animal models										
OCSPP 890.1100, OECD TG 231 ^e	AMA (EDSP Tier 1)	Metamorphosis	—	—	—	—	X	Growth (e.g., BW, HLL, SVL), develop- mental progression	Reduced survival, arrested or impaired metamorphosis	OECD 2018a; U.S. EPA 2009
OCSPP 890.2300, OECD TG 241 ^a	LAGDA (EDSP Tier 2)	Metamorphosis	—	—	—	—	X	Growth (e.g., BW, SVL), developmen- tal progression	Reduced survival, arrested or impaired metamorphosis	OECD 2018e; U.S. EPA 2009
OCSPP 890.2100	Avian two-gen toxicity test (EDSP Tier 2)	Parent, offspring	X	X	—	X	X	Embryonic, hatchling, and chick malformations	Reduced survival, impaired hatchling, chick development	U.S. EPA 2009

Note: *In vivo* data collected under regulatory test guidelines can be mapped along an adverse outcome pathway (AOP) from early key events that indicate thyroid activity with high specificity to downstream biological responses and adverse outcomes that may or may not occur via a thyroid mechanism. Currently, no *in vitro* regulatory guidelines test chemical interactions with molecular targets in thyroid axis. —, Not applicable; AMA, amphibian metamorphosis assay; BW, body weight; CDT, comparative developmental thyroid; CNS, central nervous system; EDSP, Endocrine Disruptor Screening Program; EOGRT, extended one-generation reproduction test; F0, parental generation; F1, offspring, first generation; HLL, hind leg length; LAGDA, larval amphibian growth and development assay; OCSP, Office of Chemical Safety and Pollution Prevention; OECD, Organisation for Economic Co-operation and Development; opt, optional end point; PNS, peripheral nervous system; SVL, snout vent length; TG, test guideline; TSH, thyroid stimulating hormone; X, required end point.

^aU.S. EPA and OECD test guidelines harmonized with one another to minimize duplications and variations in test methodologies.

^bThe 90-d and 28-d repeated-dose toxicity studies include additional test methodologies for inhalation and dermal dosing of test animals, depending on observed or predicted routes of exposure.

^cUnder U.S. EPA test guidelines, specific hormone measures in serum are not required (OCSP 870.3800, 3700) or recommended for consideration if the test chemical is known or suspected to have an effect (OCSP 870.3050, 3100, .3650).

^dCDT (comparative developmental thyroid) assay in rats is a non-guideline study that has been required by the U.S. EPA's Office of Pesticide Programs to supplement reproductive toxicity testing with thyroid-related data in pregnant and nursing dams, their fetuses, and offspring (U.S. EPA 2005).




Figure 1. An adverse outcome pathway (AOP) begins with a molecular initiating event (MIE) and terminates in an adverse outcome that is linked by a series of intermediate key events (KEs) at increasing levels of biological organization. Adverse outcomes at the organism level are used in human health risk assessment and typically with plausible linkages to the population level for ecological risk assessment. A simplified example of an AOP network is presented whereby three MIEs shown in the first column (shaded green) elicit specific cellular responses in the next three columns (KE1, KE2, KE3; shaded orange) that converge in shared organ pathology (KE4) and mediate downstream organ system alterations (KE5) to produce divergent adverse outcomes at the organism (AO1, AO2) and population (AO3) levels as shown in the last two columns (shaded red).

format using an adenovirus that expresses human DIO1, and was optimized to detect DIO1 inhibition by chemicals in the ToxCast phase 1 library (Hornung et al. 2018). This assay is currently being used to design *in vitro* HTS assays to evaluate chemical inhibition of DIO2 and DIO3 (Olker et al. 2019). Chemicals also may act as ligands that can bind TH distributor proteins, notably transthyretin (TTR), and to a lesser extent thyroid binding globulin (TBG), in serum and cerebrospinal fluid (CSF) to displace native thyroxine (T4) (Brouwer et al. 1986; Cheek et al. 1999; Ishihara et al. 2003; Meerts et al. 2000; Ren and Guo 2012; Weiss et al. 2009). Although the overall *in vivo* relevance of chemical interference with serum TH distributors remains unclear, a surface plasmon resonance–based biosensor assay for TTR and TBG is available that provides medium- to high-throughput testing capabilities with commercially available technologies (Marchesini et al. 2006, 2008).

Another mechanism by which chemicals decrease circulating concentrations of TH is by activation of hepatic xenobiotic nuclear receptors (NRs) leading to inductions of phase I, II, and III metabolic enzymes and transporters in the liver and other tissues. Enhanced phase II TH glucuronidation and sulfation catalyzed by uridine diphosphate glucuronosyltransferases (UDPGTs) and sulfotransferases (SULTs), respectively, can increase TH catabolism and reduce serum TH by accelerating clearance (Barter and Klaassen 1994; Hood et al. 2003; Yu et al. 2009; Zhou et al. 2002). *In vitro* HTS assays are available in ToxCast to assess chemical binding and activation of specific xenobiotic NRs [e.g., constitutive androstane receptor (CAR); pregnane X receptor (PXR); aryl hydrocarbon receptor (AhR)]. Once bound, activation of these NRs may up-regulate expression of phase I (CYP450s) and phase II [e.g., UDP glucuronosyltransferase family 1 member A1 and member A6 (*UGT1A1* and *UGT1A6*, respectively), Sulfotransferase family 2A member 1 (*SULT2A1*)] genes encoding isoenzymes involved in T4 glucuronidation and sulfation. *In vitro* HTS assays measuring induction and/or inhibition of TH conjugating enzymes, as well as the transporters mediating cellular transport of TH, are under development.

With regard to receptor–ligand interactions, screening of the Tox21 chemical library of 10,000 chemicals using transactivation assays aimed at TR α and TR β indicate that binding is restricted to a limited number of chemicals (Freitas et al. 2011, 2014; Houck et al. 2018; U.S. EPA 2015a). Likewise, chemical interactions with the thyrotropin releasing hormone receptor (TRHR) and thyroid

stimulating hormone receptor (TSRH) do not appear to be prominent sites for chemical binding (Gershengorn and Neumann 2012; Murk et al. 2013); however, this is an area with limited research and analysis of the ToxCast/Tox21 screening data is underway (Paul Friedman et al. 2017; Shobair et al. 2019).

Thyroid AOP Network as Framework for Chemical Screening and Assessment

The thyroid AOP network in Figure 2 illustrates how *in vitro* HTS assays (under development or currently available) identified in Table 2 can be mapped to this network of KEs that chart a progressive path to adverse outcomes. The thyroid AOP network serves as the foundation to organize and evaluate thyroid data, identify data gaps, and examine the evidence for causality between KEs in AOPs. These KE relationships connecting MIEs to KEs and adverse outcomes in Figure 2 may be considered hypothesized, correlative, or causal depending on the strength of the evidence (e.g., Coady et al. 2017; Crofton and Zoeller 2005; Degitz et al. 2005; Hassan et al. 2017; Miller et al. 2009; Murk et al. 2013; Perkins et al. 2013; Zoeller and Crofton 2005).

Another important application of the thyroid AOP network is to clarify research needs for decision making. *In vitro* HTS assays currently available to measure MIEs are shown in Figure 2 with solid borders in the left-hand column (and also shaded green), and end points collected as part of U.S. EPA and OECD guidelines (Table 1) are shown with thick red borders. Several MIEs in Figure 2 and further summarized in Table 2 do not yet have *in vitro* HTS assays even though in some instances lower-throughput *in vitro* assays are available (e.g., for UDPGT/SULT activity). In addition, results from studies published in peer-reviewed literature may be another source of data to further populate the AOP network. The peer reviewed literature may be particularly helpful in identifying and characterizing KEs downstream of serum TH and proximal to adverse outcomes as current regulatory test guidelines (Table 1) provide limited coverage.

Advancements of methods for systematic review and evidence integration provide approaches to identify and evaluate peer-reviewed studies for relevance, performance, and reliability to support their inclusion in chemical assessment (Hoffmann et al. 2017; Rooney et al. 2014; National Academies of Sciences, Engineering, and Medicine 2018). An increasing number of omic studies also




Figure 2. Adverse outcome pathway (AOP) network for chemically induced thyroid activity showing the integration of multiple individual AOPs under development and proposed. Biological linkages described may be informed by *in vitro*, *in vivo*, or computational data and may be causal, inferential, or putative, depending on the strength of the evidence. Boxes with thick, red borders represent *in vivo* end points that are targeted by U.S. EPA and OECD test guidelines. In the left-hand column, MIE boxes with solid borders (shaded green) represent current MIEs with *in vitro* high-throughput screening (HTS) assays that have demonstrated reliability and are available for use in thyroid activity screens, whereas those with dashed borders represent putative MIEs in the thyroid axis currently without *in vitro* HTS capabilities. In the key events (KEs) column, the box with the striped background (shaded yellow) depicts changes in serum TH as a KE node that represents a biomarker of thyroid disruption, whereas the trapezoids (shaded blue) represent additional potential KE nodes with limited data. Uppercase nomenclature denoting human protein is shown although present in differing species. Asterisks represent KEs being treated as MIEs. References and AOPs supporting the thyroid AOP network are identified in Table 2. AhR, aryl hydrocarbon receptor; BDNF, brain-derived neurotrophic factor; CAR, constitutive androstane receptor; DIO, iodothyronine deiodinase; DIO1, type 1 deiodinase; DIO2, type 2 deiodinase; DIO3, type 3 deiodinase; DUOX, dual oxidase; IYD, iodotyrosine deiodinase; LDL, low-density lipoprotein; MDR, multidrug resistance protein; MCT, monocarboxylate transporter; NIS, sodium-iodide symporter; OATP, organic anion transporter polypeptide; OECD, Organisation for Economic Co-operation and Development; PPAR, peroxisome proliferator-activated receptor; PXR, pregnane X receptor; rT3, reverse T3 (3,3',5'-triiodothyronine); RXR, retinoid X receptor; SULT, sulfotransferase; T3, 3,3',5'-triiodothyronine; T4, thyroxine; TBG, thyroid binding globulin; TH, thyroid hormone; TPO, thyroperoxidase; TR, thyroid hormone receptor; TRHR, thyrotropin releasing hormone receptor; TSHR, thyroid stimulating hormone receptor; TTR, transthyretin; UDPGT, uridine diphosphate glucuronosyltransferase.

describe chemical effects on genes (transcriptomics), proteins (proteomics), and low-molecular-weight biomolecules (metabolomics) in the thyroid gland and TH-responsive tissues, including several transcriptomic studies (Boucher et al. 2014; Crump et al. 2002; Huang et al. 2011; Haggard et al. 2018b; Ohara et al. 2018; Porreca et al. 2016; Royland et al. 2008). For example, chromatin immunoprecipitation with microarray (ChIP-on-chip) and DNA sequencing (ChIP-seq) have been used in genome-wide analyses to identify putative TR target genes in human cancer cell lines (Chung et al. 2016), mouse liver (Grøntved et al. 2015; Ramadoss et al. 2014), mouse brain (Compe et al. 2007; Dong et al. 2009), and frog intestine (Fu et al. 2017). There are now a handful of studies reporting chemical effects on thyroid-related proteomics (e.g., Williams et al. 2016; Lee et al. 2018; Serrano et al. 2010) and

metabolomics (e.g., SSY Huang et al. 2016; Houten et al. 2016; Johnson et al. 2012). Cell-based assays and transgenic animal models have also been deployed to elucidate molecular targets, toxicity pathways, and chemical structure-activity relationships of thyroid disruption (Gentilcore et al. 2013; Jarque et al. 2018; Ji et al. 2012; Opitz et al. 2012; Rosenberg et al. 2017). To this end, recent advances in genome editing tools with toxicological applications, notably clustered, regularly interspaced, short palindromic repeats (CRISPR)-Cas9 technologies have been used to better understand TH signaling pathways (Kyono et al. 2016; Markossian et al. 2018; Sakane et al. 2018; Trubiroha et al. 2018; Yang et al. 2018). However, despite these advances, inclusion of *in vitro* genotyping studies in chemical assessment is still rare, and current efforts seek to standardize methods and link genetic outcomes to phenotypic

Table 2. Identification of known and putative molecular targets [i.e., molecular initiating events (MIEs) and key events (KEs) being treated as MIEs] of chemical-induced thyroid disruption.

Molecular initiating event	Toxicological mechanism ^a	In vitro HTS assay readiness ^b	Potential adverse outcomes ^c	References
TH synthesis (thyroid gland) Sodium–iodide symporter (NIS)	Regulates serum iodide uptake into thyroid follicular cells and other tissues. Inhibition of NIS-iodide transport disrupts T4 and T3 synthesis. Well-characterized chemical target in thyroid pathway. <i>Chemicals:</i> <i>perchlorate, chlorate, nitrate, thiocyanate, small ion drugs</i>	Existing: Hallinger et al. 2017; Wang et al. 2018	Mammals: Developmental neurotoxicity, cognitive defects Amphibians: Impaired metamorphosis Birds: Delayed hatching, increased mortality, decreased growth <i>ACPs</i> 54, 110, 134, 176	<i>In vivo</i> studies: Gilbert and Sui 2008; Goleman et al. 2002; McNabb et al. 2004; Tiege et al. 2005, 2010; York et al. 2004 <i>In vitro</i> studies: Chen et al. 2008 Reviews: NRC 2005
Thyroperoxidases (TPO)	Catalyzes oxidation of iodide, nonspecific iodination of tyrosyl residues of thyroglobulin (Tg), and coupling of iodotyrosyls to form Tg-bound T3 and T4. Inhibition of TPO activity disrupts TH synthesis. Well-characterized chemical target in thyroid pathway. <i>Chemicals:</i> <i>methimazole, PTU, propylthiouracil, soy isoflavones, mancozeb, resorcinol, triclosan</i>	Existing: Paul Friedman et al. 2016	Mammals: Visual deficits, developmental neurotoxicity, cognitive defects; MOA/AOP development neurotoxicity in rat Rat: Thyroid cancer Amphibians: Impaired metamorphosis Fish: Reduced swim bladder inflation <i>ACPs</i> 42, 119, 159, 175, 271 2005	<i>In vivo</i> studies: Ausó et al. 2004; Boyes et al. 2018; Degitz et al. 2005; Fort et al. 2000; Gilbert 2011; Gilbert et al. 2013, 2016; Goodman and Gilbert 2007; Lasley and Gilbert 2011; Nelson et al. 2016; O'Shaughnessy et al. 2018a, 2018b; Stinkens et al. 2016; Zoeller and Crofton 2005
Iodotyrosine deiodinase (IYD)	Scavenges/recycles iodide in the thyroid by catalyzing deiodination to T1 and T2. Limited evidence of chemical inhibition. <i>Chemicals:</i> <i>3-nitro-L-tyrosine, OH-PCBs, OH-PBDEs, rose bengal</i>	Promising	Amphibians: Impaired metamorphosis <i>ACP</i> 188	<i>In vitro</i> studies: Davidson et al. 1978 Reviews: Dellarco et al. 2006; Hurley 1998 <i>In vivo</i> studies: Olker et al. 2018b <i>In vitro</i> studies: Shimizu et al. 2013
Pendrin	Transports iodide from cytosol of thyroid follicular cell into lumen for organification. No reports of chemical interactions; research limited. <i>Chemicals: Unknown</i>	Early	Not yet characterized <i>ACP</i> 192	—
Dual oxidase (DUOX)	Generates peroxide necessary for TH synthesis. No reports of chemical interactions. Research limited. <i>Chemicals: Unknown</i>	Early	Not yet characterized <i>ACP</i> 193	—
TH transport (serum)	Bind and distribute TH in circulation. TTR and TBG are known chemical targets. Albumin is the most abundant, but TH binding is non-specific with low affinity. <i>Chemicals:</i> <i>OH-PCBs, OH-BDEs, PFAS, TBBPA, TCBPA, genistein, dioxins</i>	Existing: Marchesini et al. 2006; Montano et al. 2012	Not yet characterized <i>ACP</i> 152	<i>In vivo</i> studies: Halgren and Darnerud 2002; Hedge et al. 2009
Iodothyronine deiodinase (DIO) Type 1 (DIO1); DIO	Control the activation and inactivation of T4 in a tissue-specific and temporal manner. With the exception of FD&C red dye no. 3 that has	Existing: DIO1: Hornung et al. 2018 DIO2, DIO3: Olker et al. 2019	Not yet characterized <i>ACPs</i> 156-158, 189-191	<i>In vitro</i> studies: Borzelleca et al. 1987; Hood and Klaassen 2000; Mol et al. 1999; Reviews: Brouwer et al. 1998
TH metabolism and excretion (liver and other target tissues)				

Note: Table adapted from Murk et al. (2013) and OECD (2014). —, Not applicable; BPA, bisphenol A; EE2, 17 α -ethynodiol (synthetic estrogen); MOA, mode of action; OH-BDE, hydroxylated bromodiphenyl ether (PBDE metabolites); OH-PCB, hydroxylated polychlorinated biphenyl ether; PCB, polychlorinated diphenyl ether; PCN, pregnenolone-16 α -carboximide; PEAS, per- and polyfluoralkyl substances; PTU, propylthiouracil; RXR, retinoid X receptor; T3, triiodothyronine; T4, thyroxine; TBBPA, tetrabromobisphenol A; TCBPA, tetrachlorobisphenol A; TRIAC, triiodothyroacetic acid; TR, thyroid hormone receptor; TRE, thyroid hormone response element; TRH, thyrotropin releasing hormone; TSH, thyroid stimulating hormone; UDPGT, uridine diphosphate glucuronosyltransferase.

^aThe toxicological mechanism column highlights the role of MIEs in thyroid hormone (TH) signaling along with chemicals shown to interact with them.

^b*In vitro* HTS assay development denoted as “promising” indicates MIEs in the thyroid axis for which there is interest and/or activity in developing *in vitro* HTS approaches, typically with supportive *in vivo* and slow- or medium-throughput *in vitro* toxicity studies indicating chemical interactions. *In vitro* HTS readiness denoted as “early” indicates putative MIEs but with limited toxicity evidence and with little current activity to develop high-throughput alternatives.

^cMIEs in the thyroid axis with evidence of linkages to adverse outcomes. Additional information on individual AOPs in development and completed can be found at <https://aopwiki.org/>.

Table 2. (Continued.)

Molecular initiating event	Toxicological mechanism ^a	In vitro HTS assay readiness ^b	Potential adverse outcomes ^c	References
Type 2 (DIO2); DIO Type 3 (DIO3)	been shown to induce thyroid tumors in rats; no studies to date have shown chemicals that exert effects on DIO expression and/or activity to directly manifest in adverse outcomes.			Morse et al. 1993; Noyes et al. 2011, 2013; Szabo et al. 2009 <i>In vitro</i> studies: Butt et al. 2011; Capen and Martin 1989; Ferreira et al. 2002; Olker et al. 2019; Renko et al. 2015
Constitutive androstane receptor (CAR); Pregnane X receptor (PXR); Aryl hydrocarbon receptor (AhR)	Xenobiotic nuclear receptors that up-regulate expression of phase I and II metabolic enzymes and phase III uptake and efflux transporters, some of which may accelerate TH catabolism and clearance. Chemicals: See UDPGTs and SULTs	Existing: ToxCast/Tox21 He et al. 2011; Maglich et al. 2003; Romanov et al. 2008; Rosenfeld et al. 2003	See UDPGTs and SULTs	See UDPGTs and SULTs
Uridine diphosphate glucuronosyltransferase (UDPGTs; e.g., UGT1A1, UGT1A6); sulfotransferases (SULTs; e.g., SULT2A1)	Major phase II chemical conjugation pathways that also regulate TH catabolism. Chemical up-regulation in the expression and activity of UDPGTs and SULTs increase T4 glucuronidation and sulfation, respectively. There are numerous isoforms of UDPGTs and SULTs, with UGT1A1, UGT1A6, and SULT2A1 having been shown to metabolize T4. Chemicals: OH-BDEs, OH-PCBs, PAHs, PFAS, BPA, triclosan, dioxins, propiconazole, phthalates, phenobarbital, rifampicin, PCN	Promising	UDPGTs: Mammalian cochlear damage and hearing loss; MOA/AOP hearing deficits via up-regulated TH catabolism. AOPs 8, 194	<i>In vivo</i> studies: Barter and Klaassen 1992, 1994; Haines et al. 2018; Klaassen and Hood 2001; Szabo et al. 2009; Vansell and Klaassen 2002; Visser et al. 1993; Wong et al. 2005; Yu et al. 2009
Alanine side-chain reactions	T4 and T3 alanine side-chains can be metabolized by oxidative decarboxylation or deamination, producing thyronamines and thyroacetic acids, respectively. Chemicals: Unknown	Early	SULTs: Not yet characterized	<i>In vitro</i> studies: Butt and Stapleton 2013; Larson et al. 2011; Rotroff et al. 2010; Schuur et al. 1998 Reviews: Crofton and Zoeller 2005; Kommo et al. 2008; Wang and James 2006 Reviews: Scanlan 2009; Wu et al. 2005
Peroxisome proliferator-activated receptor (PPAR α , PPAR β/δ , PPAR γ)	Key regulators controlling lipid and carbohydrate metabolism, as well as in mediating cellular differentiation and proliferation, and reproductive development. PPARs and TRs bind to DNA response elements as heterodimers with the RXR and other NRs and have been shown to compete for binding with RXR as well as for TR-transcriptional coactivators and corepressors. Chemicals: PFAS, PBDEs, phthalates, BPA, TBBPA, TCBPA, organochlorine pesticides, EE2, fibrate drugs, Wy14,643, rosiglitazone, thiazolidinediones	Existing: ToxCast/Tox21: R Huang et al. 2016; Martin et al. 2010; Romanov et al. 2008; van Raalte et al. 2004	Not yet characterized	<i>In vivo</i> studies: Lake et al. 2016; Springer et al. 2012 <i>In vitro</i> studies: Huang et al. 2011; Juge-Aubry et al. 1995 <i>In silico</i> studies: Nolte et al. 1998 Reviews: Hyvri and Portman 2006; Lu and Cheng 2010; Miller et al. 2009; White et al. 2011
TH transport (cellular)	MCT8 is a specific cellular transporter of TH, and MCT8 mutations produce hypothyroidism and severe neurological impairments. MCT10, OATP1C1, and OATP1A4 mediate transport TH and other ligands. There are numerous	Early	Not yet characterized	<i>In vivo</i> studies: Braun et al. 2012; Heuer et al. 2005; Noyes et al. 2013; Richardson et al. 2008; Roberts et al. 2008; Sharlin et al. 2018; Song et al. 2016; Westholm et al. 2009

Table 2. (Continued.)

Molecular initiating event	Toxicological mechanism ^a	In vitro HTS assay readiness ^b	Potential adverse outcomes ^c	References
	other transporters that have been shown to transport TH, including several other subtypes of OATPs and L-type amino acid transporter (LAT1, LAT2). Limited evidence that some chemicals may alter expression. <i>Chemicals:</i> <i>PBDEs, TRAC, PBDEs</i>			<i>In vitro</i> studies: Dong and Wade 2017; Friesema et al. 2003 Reviews: Visscher et al. 2011
Multidrug resistance protein (MDR1); multidrug resistance associated protein (MRP2)	Phase III hepatic efflux transporters that mediate hepatobiliary efflux of xenobiotics and TH. Importance as a chemical target is unclear. <i>Chemicals:</i> <i>PBDEs, anxiolytic/antiepileptic drugs</i>	Early	Not yet characterized	<i>In vivo</i> studies: Richardson et al. 2008; Szabo et al. 2009; Wong et al. 2005
Receptor-ligand binding TRH receptor	Controls synthesis and release of TSH; TRH mutations lead to hypothyroidism. <i>Chemicals: Unknown</i>	Promising: ToxCast/Tox21	Not yet characterized	<i>In silico</i> studies: Engel et al. 2008; Knudsen et al. 2011; Sipes et al. 2013 Reviews: Beck-Peccoz et al. 2006
TSH receptor	When activated, stimulates adenylyl cyclase and formation of cAMP that increases iodide uptake and TH synthesis in thyroid follicular cells. <i>Chemicals: Unknown</i>	Promising: ToxCast/Tox21	Not yet characterized	<i>In vitro</i> studies: Jomaa et al. 2013; Neumann et al. 2009; Santini et al. 2003; Titus et al. 2008 <i>In silico</i> studies: Paul Friedman et al. 2017; Shobair et al. 2019
TR binding and transactivation (TR α , TR β)	Transcription factors that have ligand (T3)-dependent and -independent activity. In humans, THRA genes encode TR α 1, TR α 2, and TR α 3 and truncated isoforms. THRB genes encode TR β 1, TR β 2, and TR β 3 (possibly rat only) and truncated isoforms. Only TR α 1, TR β 1, TR β 2, and TR β 3 can bind T3 and TRES; TR β 1 and TR β 2 regulate TRH in the hypothalamus. Some chemicals bind TRs as antagonists and/or modify transcription; however, screens of chemical libraries suggest binding is restricted. <i>Chemicals:</i> <i>TBBPA, TCBPA, BPA, OH-PCBs, OH-BDEs, triclosan</i>	Existing: ToxCast/Tox21: Freitas et al. 2011, 2014	Not yet characterized	Reviews: Gershengorn and Neumann 2012 <i>In vivo</i> studies: Dupré et al. 2004 <i>In vitro</i> studies: Cheek et al. 1999; Clerget-Froidevaux et al. 2004; Freitas et al. 2011, 2014; Gauger et al. 2007; Hofmann et al. 2009; Huang et al. 2011; Kitamura et al. 2002, 2005; Kojima et al. 2009; Moriyama et al. 2002; Schriks et al. 2006; Sun et al. 2009; You et al. 2006 <i>In silico</i> studies: Knudsen et al. 2011; Politi et al. 2014; Romanov et al. 2008; Sipes et al. 2013 Reviews: Zoeller 2005




Figure 3. Adverse outcome pathways (AOPs) for select chemical pathways of thyroid disruption, including (A) rat thyroid follicular cell tumors linked to chemical inhibition of TPO; (B) impaired cognitive functioning in mammals linked to chemical inhibition of TPO; and (C) hearing deficits in mammals linked to inductions of TH catabolic pathways. In the left-hand column, MIE boxes activated for a given pathway are shown with solid borders (shaded green) and KEs in the AOPs are shown as boxes with striped background (shaded orange). The causative KE in the formation of rat thyroid tumors (A) is increasing TSH (shown with thick borders and striped background and shaded orange) leading to hypothalamic–pituitary compensatory feedback responses shown in left-hand MIE boxes and downstream thyroid hypertrophy and hyperplasia with striped background (and also shaded orange). In contrast, elevated TSH (shown with a dashed border) has not been shown as a causative KE in chemical inhibition of TPO leading to cognitive impairments in mammals (B) or chemical activation of the hepatic xenobiotic NR response cascade leading to mammalian hearing deficits (C). References supporting these AOPs can be found in Table 2. \leftrightarrow , no change from reference controls; AhR, aryl hydrocarbon receptor; CAR, constitutive androstane receptor; KE, key event; MIE, molecular initiating event; NR, nuclear receptor; PXR, pregnane X receptor; T3, 3,3',5-triodothyronine; T4, thyroxine; TPO, thyroperoxidase; TH, thyroid hormone; TR, thyroid hormone receptor; TRH, thyrotropin releasing hormone; TRHR, thyrotropin releasing hormone receptor; TSH, thyroid stimulating hormone; TSHR, thyroid stimulating hormone receptor; UDPGT, uridine diphosphate glucuronosyltransferase.

anchors representing adverse outcomes (Buesen et al. 2017; Bourdon-Lacombe et al. 2015; Brazma et al. 2001; Dean et al. 2017; Thomas et al. 2013a, 2013b; Villeneuve et al. 2012; Wang et al. 2016).

Assembling and interpreting the scientific evidence measured in independent *in vitro*, *in silico*, and *in vivo* research efforts presents an enormous challenge for chemical assessment. The

thyroid AOP network provides architecture to begin mapping and integrating diverse data to characterize chemical interactions with the thyroid axis. New *in vitro* technologies incorporated into pathway-based approaches are anticipated to help reduce uncertainties and resolve some of the major challenges that are examined below and presented by these evaluations.

Regulatory Challenges in Evaluating and Linking Thyroid MIEs to Adverse Outcomes

Currently, no U.S. EPA or OECD *in vitro* regulatory guidelines test chemical interactions with MIEs in the thyroid axis (Table 1). For most regulatory requirements, hazards are identified for individual chemicals and there are little to no data describing the combined effects of individual chemicals and chemical mixtures that interact with multiple MIEs in the thyroid axis. In addition, current guidelines can detect some thyroid-related disturbances (e.g., changes in serum TH) that have been used to derive hazard values for regulatory purposes, but it is not possible to attribute an adverse outcome to a mechanism. Neither have intermediate parameters (KE and KE relationships) linking an adverse outcome to an upstream MIE been empirically quantified in most cases.

By depicting points where several MIEs converge at shared KEs, the AOP network helps to identify nodes around which assays can be developed to link MIEs to adverse outcomes and clarify data that would be most relevant for regulatory applications. For example, uncertainties continue as to dose-response relationships in chemical-induced changes in serum TH, particularly milder TH perturbations that result in adverse outcomes (Crofton 2004). For example, AOPs (Figure 2; Table 2) describe chemical inhibition of NIS and TPO leading to reduced TH production and decreased serum T4 that culminate in delayed/arrested amphibian development (AOP 176, AOP 175, respectively) and impaired mammalian neurodevelopment (AOP 134, AOP 42, respectively). However, a quantitative understanding of KE relationships in the TPO- and NIS-related AOPs is limiting, although current efforts are beginning to quantify these interactions (Gilbert and Sui 2008; Hassan et al. 2017; O'Shaughnessy et al. 2018b). Decision makers can use the biological plausibility embedded in the thyroid AOP network to clarify linkages for characterization and identify gaps in available knowledge. From this information, KE relationships can be proposed for quantification to support predictive modeling and hazard assessment, as well as reduce data uncertainties.

Differential Species and Life Stage Sensitivities; Interpreting Biomarkers

Future work to expand and refine the thyroid AOP network can help to identify physiological similarities and differences between KEs and KE relationships spanning vertebrate classes. The characterization of shared toxicity mechanisms leading to divergent adverse outcomes across species can be useful in the translation of research between nonmammalian and mammalian species including humans. For example, chemical inhibition of thyroid gland TPO can reduce serum and tissue TH that alter tissue-specific genomic signaling and elicit species- and life stage-specific adverse outcomes [e.g., abnormal brain development in mammals (Zoeller and Crofton 2005); impaired metamorphosis in amphibians (Coady et al. 2010; Hornung et al. 2015; Tietge et al. 2010); reduced anterior swim bladder inflation in teleost fish (Nelson et al. 2016; Stinckens et al. 2016)]. Identification of shared KEs as integrative nodes facilitates characterization of diagnostic biomarkers across species that can be represented in predictive modeling and evaluated in organismal assays to further support mechanistic linkages between KEs and adverse outcomes (Crofton 2008; Miller et al. 2009; Paul et al. 2013; Perkins et al. 2013).

Several MIEs in the thyroid AOP network may induce a cascade of KEs proceeding through decreased serum T4 and/or triiodothyronine (T3) (Figure 2; box with striped background and shaded yellow). Changes in serum TH are a useful biomarker of

thyroid perturbation and are usually correlated to changes in tissue TH (as reviewed by Oppenheimer and Schwartz 1997; Porterfield and Hendrich 1993). However, reliance on serum TH may oversimplify subsequent linkages to downstream KEs that drive adverse outcomes. Serum TH levels are not always aligned with tissue levels as tissue TH is regulated by DIO enzymes, cellular transporters, and regional TR expression. The disconnect between altered TH signaling in the fetal brain, neurodevelopmental consequences, and serum TH has been demonstrated using several gene knock-out (KO) mouse models with deficiencies in genes encoding DIO enzymes, TRs, monocarboxylate transporter (MCT)8, organic anion transporter polypeptide (OATP)1c1, and other TH transporters (as reviewed by Bárez-López et al. 2018; Bernal 2018; Hernandez et al. 2010; Richard and Flamant 2018). For example, considerable evidence describes the contribution of DIO enzymes, particularly DIO2 and DIO3, in the maintenance of T3 in TH-responsive regions of the developing brain [i.e., DIO2 predominantly in astrocytes; DIO3 predominantly in neurons; as reviewed by Bianco et al. (2002), Guadaño-Ferraz et al. (1997), Morreale de Escobar et al. (2008), Patel et al. (2011), and Zoeller (2010)]. However, studies show that *Dio2* and *Dio1/Dio2* KO mouse models with deficient tissue capacity to produce T3 do not experience substantial deficits in motor, learning, or memory functioning, although other deficits (e.g., impaired cochlear and visual development) do occur (Galton et al. 2007, 2009, 2014; Obregón et al. 1991; Schneider et al. 2001; Schneider et al. 2006). These *Dio1/Dio2* KO strains exhibit regionally specific reductions in brain T3 but normal serum T3, as well as elevated serum and tissue T4. In contrast, the *Dio3* KO fetus and newborn pup exhibit an initial hyperthyroidism followed by hypothyroidism, impaired growth and fertility, and reduced survival. Elevations in serum and brain T3 are accompanied by an initial acceleration and subsequent delay of T3-inducible gene expression in the brain (Hernandez et al. 2010). Subsequent experiments have shown that *Dio3* KO mice with augmented brain TH exhibit hyperactivity and reduced anxiety-like behaviors despite systemic hypothyroidism as indicated by reduced serum T3 (Stohr et al. 2016).

As these examples illustrate, the lack of change in serum TH is not a guarantee that TH effects in tissues are not occurring, and conversely changes in serum TH are not always predictive of adverse outcomes. Possible explanations for the lack of concordance between serum TH and adverse outcomes may relate to the not yet fully characterized age- and regional-specific responses of the brain to compensate to systemic TH insufficiency. Nonetheless, fetal and early postnatal susceptibilities to thyroid toxicants are heightened because their thyroid feedback systems are absent or incompletely formed and they have low TH reserves that are critical to neurological development (as reviewed by Morreale de Escobar et al. 2004a; Skeaff 2011; Williams 2008; and Zoeller and Rovet 2004). The thyroid AOP network provides a tool to map linkages and identify possible KEs for further characterization and quantification (e.g., trapezoid boxes also shaded blue in Figure 2) to aide in predicting adversity. For purposes of decision making, changes in serum TH profiles are not prescriptive to either mechanisms or outcomes, but they nevertheless do provide clear indication of perturbed thyroid homeostasis with the potential to adversely affect development.

The thyroid AOP network also can identify KEs that may not fall on the causative pathway leading to an adverse outcome, making these KEs potentially less relevant to decision making. One such example is the stimulation of the thyroid–pituitary feedback response (i.e., increased TSH). Although TSH increases often accompany exposure to a number of thyroid disrupting chemicals, TSH is not a causative KE in AOPs involving TPO inhibition that result in impaired hippocampal development and cognitive deficits (Zoeller and Crofton 2005) and up-regulated

TH catabolism leading to ototoxicity (Crofton and Zoeller 2005) (Figure 3). For example, rat offspring developmentally exposed to some polychlorinated biphenyls (PCBs) and dioxins experience mainly hypothyroxinemia (i.e., reduced serum T4 with TSH in reference control ranges) that culminate in impaired cochlear development and hearing loss (Crofton et al. 2000; Crofton 2004; Goldey et al. 1995; Morse et al. 1993; Sher et al. 1998). Elevated TSH in rodents leads to thyroid hypertrophy and potential thyroid cancer, an adverse outcome that has limited relevance to human thyroid cancer due to species differences in sensitivity (Capen and Martin 1989; EU 2017; Hurley 1998; McClain et al. 1988), although this too is an area of renewed interest (EU 2017). Thus, elevated TSH may not be a reliable KE biomarker for thyroid cancer in humans, but increased TSH in rodents does indicate a chemical capable of perturbing TH signaling in other species, including humans, and is involved in other thyroid-responsive outcomes, including neurodevelopment.

Understanding pathway conservation is critical for cross-species extrapolation and requires understanding the conservation of protein targets (e.g., MIEs) and resulting sensitivity to chemicals. Research efforts in this area range from *in vivo* exposures across phylogenetically disparate species, followed by toxicogenomic meta-analyses (Garcia-Reyero et al. 2011), to bioinformatics comparing amino acid sequences/functional domain similarity across species to identify putative functional orthologues (LaLone et al. 2013). For purposes of chemical screening and *in vitro* HTS assay development, a basic demonstration of cross-species concordance of chemical activity is sufficient to provide confidence that the representative *in vitro* system is reliable for generating screening-level data. For example, strong cross-species concordance in the activity of porcine and rat TPO has been shown despite only 75% amino acid similarity in the conserved peroxidase domain (Paul et al. 2013). Results from numerous *in vivo* exposures to select TPO-active chemicals in fish (Doerge et al. 1998; Nelson et al. 2016; Stinckens et al. 2016), amphibians (Coady et al. 2010; Hornung et al. 2015; Tietge et al. 2010, 2013), birds (Grommen et al. 2011; Rosebrough et al. 2006), and mammals (Davidson et al. 1978; Divi and Doerge 1996; Francis and Rennert 1980) corroborate the conserved mechanistic linkages leading to species-specific adverse outcomes. Such information can define circumstances under which screens for thyroid activity can benefit from combining lines of evidence across species with shared KEs, as opposed to situations when species-specific data support being separated for regulatory use.

Human Relevance of Hepatic- and Serum Distributor-Driven TH Effects in Rodents

The observation of thyroid-related end point changes in rodents and their relevance to predicting adverse outcomes in humans continues to present research questions. One such data gap concerns interpreting the human applicability of chemical-induced TH reductions in rodents through activation of xenobiotic NRs, notably PXR and CAR, and up-regulation of hepatic TH catabolism (Figures 2–3; Table 2) (EU 2017; ECHA 2016). Although functionally conserved in many cases (e.g., CYP450s), hepatic drug metabolizing enzymes have differing isoform compositions, substrate selectivity, and catalytic activities depending on species, life stage, and genetics that may affect chemical and TH biotransformation (Benedetti et al. 2005; Curran and DeGroot 1991; Kondo et al. 2017; Martignoni et al. 2006; Nebert and Gonzalez 1987).

Increased hepatic catabolism of TH, along with reductions in serum TH and elevated TSH, are well described in rodents (rat, mouse, hamster) exposed to hepatic enzyme-inducing chemicals such as phenobarbital, some PCBs (Aroclor 1254), pregnenolone-16 α -carbonitrile, and 3-methylcholanthrene (Barter and Klaassen

1994; Haines et al. 2018; Hood et al. 2003; Kato et al. 2010; Klaassen and Hood 2001; Vansell and Klaassen 2002; Wong et al. 2005). Studies in human subjects also demonstrate the responsiveness of TH catabolic pathways to hepatic enzyme inducers (Benedetti et al. 2005; Christensen et al. 1989; Curran and DeGroot 1991; Ohnhaus et al. 1981; Rootwelt et al. 1978; Yeo et al. 1978; Zhang et al. 2016). In contrast with rodents, human serum T4 decrements reported in these studies are varied and typically not accompanied by changes in TSH, suggesting the possibility of milder responses in humans compared with rodents, although this may not be the case in sensitive subpopulations. For example, studies in healthy human test subjects receiving therapeutic doses of the human CAR activator phenobarbital and other antiepileptic drugs show unchanged or decreased serum TH, with generally no TSH alterations (as reviewed by Benedetti et al. 2005; Curran and DeGroot 1991). Similarly, healthy human subjects receiving therapeutic doses of the antibiotic and human PXR agonist rifampicin exhibit reduced serum T4, as well as increased T4 and rT3 clearance, with no change in TSH (Christensen et al. 1989; Ohnhaus et al. 1981). However, a meta-analysis of published clinical studies that examined TH end points in epileptic patients treated with phenobarbital and other antiepileptic drugs detected an overall decrease in serum T4 (no change in T3) and increase in TSH (Zhang et al. 2016), suggesting genetics and health status may influence sensitivity. The antibacterial tricosan, known to decrease serum TH in rats, has also been shown to activate human PXR, but not rat or mouse PXR, and to behave as an inverse agonist to human CAR1 and weak agonist of human CAR3 and rat/mouse CAR (Paul et al. 2013). Thus, current evidence supports that chemicals may induce hepatic TH catabolism in both humans and rodents, albeit by possibly differing metabolic pathways and potencies (an unknown at this time). Whether responses in humans extend to other chemicals as a general phenomenon is unclear, and differing exposure durations and responses between rodents and humans may be relevant to extrapolations from one species to another. Useful follow-up analyses of chemicals suspected of NR activation could involve evaluation of species selectivity of the NR response to the chemical itself.

It has also been posited that TH metabolic clearance responses in rats are less relevant to humans because TBG, the major serum TH distributor protein in humans, is less prominent in the adult rat, although it does play an important role in thyroid homeostasis in newborn and neonatal rat pups (Savu et al. 1991; Young et al. 1988). In adult rodents, amphibians, birds, and fish, TTR appears to be the major serum TH distributor protein (Dickson et al. 1985; Harms et al. 1991; Power et al. 2000). TTR has a lower binding affinity for T4 than TBG, and this is thought to be responsible for the shorter T4 half-life in rats (~12–24 h) than in humans (~5 d) (Lewandowski et al. 2004). Unlike TBG, TTR is important in the transport of T4 across the blood–placental (Landers et al. 2009; Mortimer et al. 2012), blood–brain (Chanoine et al. 1992; Schreiber et al. 1990), and CSF–brain (Richardson et al. 2018) barriers. Thus, a role for human TTR in TH storage and transport appears critical during fetal development. Some researchers have also suggested that although TBG binds most TH in human circulation, TH dissociation rates from TTR and capillary transit times make TTR a significant distributor protein of TH in humans as well as in rodents (Alshehri et al. 2015; Mendel 1989). Taken together, current evidence supports the activation of putative MIEs and KEs in rats, encompassing xenobiotic NR activation, inductions of UDPGTs, SULTs, and TH distributor proteins are relevant pathways for consideration. In this regard, the rat serves as a conservative model for predicting human health effects. The thyroid AOP network allows for the integration of new *in vitro* mechanistic and interspecies scaling information to help relate rodent toxicity data

to human-equivalent exposures and further populate the TH catabolic pathway for use in human health assessment.

Building Predictive Models and Toxicokinetics

Because of the diversity of known and putative molecular targets in the thyroid axis, using AOPs to develop predictive models of adverse outcomes from *in vitro* data will be challenging and require additional bioassay data for KEs in the network, particularly downstream of serum TH. Although there is qualitative evidence linking the MIEs listed in Table 2 to altered serum TH, data to establish quantitative KE relationships helpful for regulatory application are lacking. Furthermore, the large diversity of genes regulated directly and indirectly by T3, the nongenomic effects of T4, and our limited knowledge of the functioning of TH during fetal development present a challenge for predicting chemical-induced adverse outcomes from *in vitro* data (as reviewed by Bernal 2018; Richard and Flamant 2018).

In humans, detrimental effects of mild TH insufficiency on fetal cognitive development are recognized as an important public health concern, and some links to chemical exposures are described (Finken et al. 2013; Ghassabian et al. 2014; Haddow et al. 1999; Korevaar et al. 2016; Moleti et al. 2011; Morreale de Escobar et al. 2000; Steinmaus et al. 2016; Vermiglio et al. 2004). The observations in humans are supported by rodent studies where neurodevelopmental impairments result from moderate and transient reductions in serum TH induced by chemical exposures (Ausó et al. 2004; Boyes et al. 2018; Gilbert 2011; Gilbert et al. 2013, 2016, 2017; Morreale de Escobar et al. 2004b). As quantitative data become available for these types of sensitive developmental responses—likely from the use of bioassays of greater biological complexity that integrate multiple MIEs and KEs—additional modeling approaches to further characterize KE relationships could be implemented to predict thyroid-related adverse outcomes and characterize accompanying uncertainties. As a first step, models that integrate *in vitro* assay results for a single KE (when multiple assays exist) and models that integrate *in vitro* assay results for more than one KE in a target tissue (e.g., thyroid gland; TPO, NIS, DIO) could be used to prioritize chemicals for further assessment and targeted *in vivo* testing. Development of a computational systems biology model of thyroid function could help simulate the potential interactions of chemicals with activity at various MIEs. Such an effort will require an investment of research to parameterize and evaluate uncertainties.

Another challenge is that chemical toxicokinetic considerations, and an understanding of potential differences among life stages and species, are not well accounted for by current *in vitro* test systems. These limitations can lead to both false positive and false negative calls in screening efforts. Developing *in vitro* predictions of thyroid perturbations is further complicated by the fact that most chemically induced effects on downstream KEs and adverse outcomes are indirect, secondary consequences to a chemically induced change in hormone regulation. We think predictions of *in vivo* adverse outcomes from *in vitro* HTS data and other new technologies will be greatly facilitated by *a*) incorporation of toxicokinetic tools to estimate metabolic bioactivation and better characterize potency and selectivity of chemicals for target tissues, and *b*) improved mechanistic and quantitative understanding of TH action on development of target organs, especially the brain.

Conclusions

Advancements in new *in vitro* technologies offer opportunities to screen chemicals for interactions with MIEs in the thyroid pathway and to anchor adverse outcomes to a thyroid mechanism. A

substantial body of knowledge exists concerning the molecular and physiological regulation of TH signaling and responses of these systems to chemical exposures (including pharmaceuticals). The thyroid AOP network described in the present work is based on decades of research and multiple consortia to evaluate relevant KEs for chemical-induced thyroid disruption. At present, the use of *in vitro* data beyond screening and prioritization for thyroid bioactivity is challenged by the complexity of potential TH-related adverse outcomes and the limited knowledge of mechanistic processes controlling such responses. Despite these knowledge gaps, we propose that the thyroid AOP network provides the necessary biological structure to organize diverse data from differing test methods, thereby serving as a useful data integration tool to assist in hazard screening for large numbers of previously untested chemicals. As more data become available, the AOP network can be further populated to help bridge knowledge gaps and identify key nodes for assay development.

Acknowledgments

The authors are grateful to T. Bahadori, National Center for Environmental Assessment, ORD, U.S. EPA; S. Schappelle, Office of Science Coordination and Policy, Office of Chemical Safety and Pollution Prevention, U.S. EPA; and R. Thomas, National Center for Computational Toxicology, ORD, U.S. EPA for their input on early drafts of this paper.

References

- Alshehri B, D'Souza DG, Lee JY, Petratos S, Richardson SJ. 2015. The diversity of mechanisms influenced by transthyretin in neurobiology: development, disease and endocrine disruption. *J Neuroendocrinol* 27(5):303–323, PMID: 25737004, <https://doi.org/10.1111/jne.12271>.
- Andersson N, Arena M, Auteri D, Barmaz S, Grignard E, Kienzler A, et al. 2018. Guidance for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009. *EFSA J* 16(6):e05311, <https://doi.org/10.2903/j.efsa.2018.5311>.
- Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, et al. 2010. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. *Environ Toxicol Chem* 29(3):730–741, PMID: 20821501, <https://doi.org/10.1002/etc.34>.
- Ausó E, Lavado-Autric R, Cuevas E, del Rey FE, de Escobar GM, Berbel P. 2004. A moderate and transient deficiency of maternal thyroid function at the beginning of fetal neocortogenesis alters neuronal migration. *Endocrinology* 145(9):4037–4047, PMID: 15087434, <https://doi.org/10.1210/en.2004-0274>.
- Bárez-López S, Obregon MJ, Bernal J, Guadaño-Ferraz A. 2018. Thyroid hormone economy in the perinatal mouse brain: implications for cerebral cortex development. *Cereb Cortex* 28(5):1783–1793, PMID: 28407057, <https://doi.org/10.1093/cercor/bhx088>.
- Barter RA, Klaassen CD. 1992. UDP-glucuronosyl transferase inducers reduce thyroid hormone levels in rats by an extrathyroidal mechanism. *Toxicol Appl Pharmacol* 113(1):36–42, PMID: 1553754, [https://doi.org/10.1016/0041-008X\(92\)90006-E](https://doi.org/10.1016/0041-008X(92)90006-E).
- Barter RA, Klaassen CD. 1994. Reduction of thyroid hormone levels and alteration of thyroid function by four representative UDP-glucuronosyltransferase inducers in rats. *Toxicol Appl Pharm* 128(1):9–17, <https://doi.org/10.1006/taap.1994.1174>.
- Beck-Peccoz P, Persani L, Calebiro D, Bonomi M, Mannavola D, Campi I. 2006. Syndromes of hormone resistance in the hypothalamic–pituitary–thyroid axis. *Best Pract Res Clin Endocrinol Metab* 20(4):529–546, PMID: 17161330, <https://doi.org/10.1016/j.beem.2006.11.001>.
- Benedetti MS, Whomslay R, Baltes E, Tonner F. 2005. Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction. *Eur J Clin Pharmacol* 61(12):863–872, PMID: 16307266, <https://doi.org/10.1007/s00228-005-0056-0>.
- Bernal J. 2005. Thyroid hormones and brain development. *Vitam Horm* 71:95–122, PMID: 16112266, [https://doi.org/10.1016/S0083-6729\(05\)71004-9](https://doi.org/10.1016/S0083-6729(05)71004-9).
- Bernal J. 2018. New insights on thyroid hormone and the brain. *Curr Opin Endocr Metab Res* 2:24–28, <https://doi.org/10.1016/j.coemr.2017.12.001>.
- Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. 2002. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. *Endocr Rev* 23(1):38–89, PMID: 11844744, <https://doi.org/10.1210/edrv.23.1.0455>.

- Borzelleca JF, Capen CC, Hallagan JB. 1987. Lifetime toxicity/carcinogenicity study of FD & C Red No. 3 (erythrosine) in rats. *Food Chem Toxicol* 25(10):723–733, PMID: 2824305, [https://doi.org/10.1016/0278-6915\(87\)90227-4](https://doi.org/10.1016/0278-6915(87)90227-4).
- Botteri Principato NL, Suarez JD, Laws SC, Klinefelter GR. 2018. The use of purified rat Leydig cells complements the H295R screen to detect chemical-induced alterations in testosterone production. *Biol Reprod* 98(2):239–249, PMID: 29272331, <https://doi.org/10.1093/biolre/iox177>.
- Boucher JG, Husain M, Rowan-Carroll A, Williams A, Yauk CL, Atlas E. 2014. Identification of mechanisms of action of bisphenol A-induced human preadipocyte differentiation by transcriptional profiling. *Obesity* (Silver Spring) 22(11):2333–2343, PMID: 25047013, <https://doi.org/10.1002/oby.20848>.
- Bourdon-Lacombe JA, Moffat ID, Deveaux M, Husain M, Auerbach S, Krewski D, et al. 2015. Technical guide for applications of gene expression profiling in human health risk assessment of environmental chemicals. *Regul Toxicol Pharmacol* 72(2):292–309, PMID: 25944780, <https://doi.org/10.1016/j.yrtph.2015.04.010>.
- Boyes WK, Degen L, George BJ, Gilbert ME. 2018. Moderate perinatal thyroid hormone insufficiency alters visual system function in adult rats. *Neurotoxicology* 67:73–83, PMID: 29684405, <https://doi.org/10.1016/j.neuro.2018.04.013>.
- Braun D, Kim TD, Le Coutre P, Köhrle J, Hershman JM, Schweizer U. 2012. Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. *J Clin Endocrinol Metab* 97(1):E100–E105, PMID: 22031512, <https://doi.org/10.1210/jc.2011-1837>.
- Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. 2001. Minimum information about a microarray experiment (MIAME)—toward standards for microarray data. *Nat Genet* 29(4):365–371, PMID: 11726920, <https://doi.org/10.1038/ng1201-365>.
- Brouwer A, Morse DC, Lans MC, Schuur AG, Murk AJ, Klasson-Wehler E, et al. 1998. Interactions of persistent environmental organohalogens with the thyroid hormone system: mechanisms and possible consequences for animal and human health. *Toxicol Ind Health* 14(1–2):59–84, PMID: 9460170, <https://doi.org/10.1177/074823379801400107>.
- Brouwer A, van den Berg KJ, Blaner WS, Goodman DS. 1986. Transthyretin (prealbumin) binding of PCBs, a model for the mechanism of interference with vitamin A and thyroid-hormone metabolism. *Chemosphere* 15(9–12):1699–1706, [https://doi.org/10.1016/0045-6535\(86\)90457-1](https://doi.org/10.1016/0045-6535(86)90457-1).
- Browne P, Judson RS, Casey WM, Kleinstreuer NC, Thomas RS. 2015. Screening chemicals for estrogen receptor bioactivity using a computational model. *Environ Sci Technol* 49(14):8804–8814, PMID: 26066997, <https://doi.org/10.1021/acs.est.5b02641>.
- Browne P, Noyes PD, Casey WM, Dix DJ. 2017. Application of adverse outcome pathways to U.S. EPA's endocrine disruptor screening program. *Environ Health Perspect* 125(9):096001, PMID: 28934726, <https://doi.org/10.1289/EHP1304>.
- Brucker-Davis F. 1998. Effects of environmental synthetic chemicals on thyroid function. *Thyroid* 8(9):827–856, PMID: 9777756, <https://doi.org/10.1089/thy.1998.8.827>.
- Buesen R, Chorley BN, da Silva Lima B, Daston G, Deferme L, Ebbels T, et al. 2017. Applying 'omics technologies in chemicals risk assessment: report of an ECETOC workshop. *Regul Toxicol Pharmacol* 91(Suppl 1):S3–S13, PMID: 28958911, <https://doi.org/10.1016/j.yrtph.2017.09.002>.
- Butt CM, Stapleton HM. 2013. Inhibition of thyroid hormone sulfotransferase activity by brominated flame retardants and halogenated phenolics. *Chem Res Toxicol* 26(11):1692–1702, PMID: 24089703, <https://doi.org/10.1021/tx400342k>.
- Butt CM, Wang DL, Stapleton HM. 2011. Halogenated phenolic contaminants inhibit the *in vitro* activity of the thyroid-regulating deiodinases in human liver. *Toxicol Sci* 124(2):339–347, PMID: 21565810, <https://doi.org/10.1093/toxsci/kfr117>.
- Capen CC. 1997. Mechanistic data and risk assessment of selected toxic end points of the thyroid gland. *Toxicol Pathol* 25(1):39–48, PMID: 9061850, <https://doi.org/10.1177/019262339702500109>.
- Capen CC, Martin SL. 1989. The effects of xenobiotics on the structure and function of thyroid follicular and C-cells. *Toxicol Pathol* 17(2):266–293, PMID: 2675279, <https://doi.org/10.1177/019262338901700205>.
- Chanoine JP, Alex S, Fang SL, Stone S, Leonard JL, Köhrle J, et al. 1992. Role of transthyretin in the transport of thyroxine from the blood to the choroid-plexus, the cerebrospinal fluid, and the brain. *Endocrinology* 130(2):933–938, PMID: 1733735, <https://doi.org/10.1210/endo.130.2.1733735>.
- Cheek AO, Kow K, Chen J, McLachlan JA. 1999. Potential mechanisms of thyroid disruption in humans: interaction of organochlorine compounds with thyroid receptor, transthyretin, and thyroid-binding globulin. *Environ Health Perspect* 107(4):273–278, PMID: 10090705, <https://doi.org/10.1289/ehp.99107273>.
- Chen Y, Sible JC, McNabb F. 2008. Effects of maternal exposure to ammonium perchlorate on thyroid function and the expression of thyroid-responsive genes in Japanese quail embryos. *Gen Comp Endocrinol* 159(2–3):196–207, PMID: 18804473, <https://doi.org/10.1016/j.ygenc.2008.08.014>.
- Christensen HR, Simonsen K, Hegedüs L, Hansen BM, Døssing M, Kampmann JP, et al. 1989. Influence of rifampicin on thyroid gland volume, thyroid hormones, and antipyrene metabolism. *Acta Endocrinol (Copenh)* 121(3):406–410, PMID: 2800919, <https://doi.org/10.1530/acta.0.1210406>.
- Chung IH, Liu H, Lin Y-H, Chi H-C, Huang Y-H, Yang C-C, et al. 2016. ChIP-on-chip analysis of thyroid hormone-regulated genes and their physiological significance. *Oncotarget* 7(16):22448–22459, PMID: 26968954, <https://doi.org/10.18632/oncotarget.7988>.
- Clerget-Froidevaux MS, Seugnet I, Demeneix BA. 2004. Thyroid status co-regulates thyroid hormone receptor and co-modulator genes specifically in the hypothalamus. *FEBS Lett* 569(1–3):341–345, PMID: 15225659, <https://doi.org/10.1016/j.febslet.2004.05.076>.
- Clewell RA, Merrill EA, Narayanan L, Gearhart JM, Robinson PJ. 2004. Evidence for competitive inhibition of iodide uptake by perchlorate and translocation of perchlorate into the thyroid. *Int J Toxicol* 23(1):17–23, PMID: 15162843, <https://doi.org/10.1080/10915810490275044>.
- Coady KK, Biever RC, Denslow ND, Gross M, Guiney PD, Holbech H, et al. 2017. Current limitations and recommendations to improve testing for the environmental assessment of endocrine active substances. *Integr Environ Assess Manag* 13(2):302–316, PMID: 27791330, <https://doi.org/10.1002/ieam.1862>.
- Coady K, Marino T, Thomas J, Currie R, Hancock G, Crofoot J, et al. 2010. Evaluation of the amphibian metamorphosis assay: exposure to the goitrogen methimazole and the endogenous thyroid hormone L-thyroxine. *Environ Toxicol Chem* 29(4):869–880, PMID: 20821516, <https://doi.org/10.1002/etc.74>.
- Collins FS, Gray GM, Bucher JR. 2008. Toxicology: Transforming environmental health protection. *Science* 319(5865):906–907, PMID: 18276874, <https://doi.org/10.1126/science.1154619>.
- Compe E, Malerba M, Soler L, Marescaux J, Borrelli E, Egly J-M. 2007. Neurological defects in trichothiodystrophy reveal a coactivator function of TFIH. *Nat Neurosci* 10(11):1414–1422, PMID: 17952069, <https://doi.org/10.1038/nn1990>.
- Crofton KM. 2004. Developmental disruption of thyroid hormone: correlations with hearing dysfunction in rats. *Risk Anal* 24(6):1665–1671, PMID: 15660619, <https://doi.org/10.1111/j.0272-4332.2004.00557.x>.
- Crofton KM. 2008. Thyroid disrupting chemicals: mechanisms and mixtures. *Int J Androl* 31(2):209–222, PMID: 18217984, <https://doi.org/10.1111/j.1365-2605.2007.00857.x>.
- Crofton KM, Kodavanti PRS, Derr-Yellin EC, Casey AC, Kehn LS. 2000. PCBs, thyroid hormones, and ototoxicity in rats: cross-fostering experiments demonstrate the impact of postnatal lactation exposure. *Toxicol Sci* 57(1):131–140, PMID: 10966519, <https://doi.org/10.1093/toxsci/57.1.131>.
- Crofton KM, Zoeller RT. 2005. Mode of action: neurotoxicity induced by thyroid hormone disruption during development—hearing loss resulting from exposure to PHAHs. *Crit Rev Toxicol* 35(8–9):757–769, PMID: 16417043, <https://doi.org/10.1080/10408440591007304>.
- Crump D, Werry K, Veldhoen N, Van Aggelen G, Helbing CC. 2002. Exposure to the herbicide acetochlor alters thyroid hormone-dependent gene expression and metamorphosis in *Xenopus laevis*. *Environ Health Perspect* 110(12):1199–1205, PMID: 12460798, <https://doi.org/10.1289/ehp.021101199>.
- Curran PG, DeGroot LJ. 1991. The effect of hepatic enzyme-inducing drugs on thyroid hormones and the thyroid gland. *Endocr Rev* 12(2):135–150, PMID: 2070777, <https://doi.org/10.1210/edrv-12-2-135>.
- Davidson B, Soodak M, Neary JT, Strout HV, Kieffer JD, Mover H, et al. 1978. The irreversible inactivation of thyroid peroxidase by methylmercaptoimidazole, thiouracil, and propylthiouracil *in vitro* and its relationship to *in vivo* findings. *Endocrinology* 103(3):871–882, PMID: 744122, <https://doi.org/10.1210/endo-103-3-871>.
- Dean JL, Zhao QJ, Lambert JC, Hawkins BS, Thomas RS, Wesselkamper SC. 2017. Editor's highlight: application of gene set enrichment analysis for identification of chemically induced, biologically relevant transcriptomic networks and potential utilization in human health risk assessment. *Toxicol Sci* 157(1):85–99, PMID: 28123101, <https://doi.org/10.1093/toxsci/kfx021>.
- Degitz SJ, Holcombe GW, Flynn KM, Kosian PA, Korte JJ, Tietge JE. 2005. Progress towards development of an amphibian-based thyroid screening assay using *Xenopus laevis*. Organismal and thyroidal responses to the model compounds 6-propylthiouracil, methimazole, and thyroxine. *Toxicol Sci* 87(2):353–364, PMID: 16002479, <https://doi.org/10.1093/toxsci/kfi246>.
- Dellarco VL, McGregor D, Berry SC, Cohen SM, Boobis AR. 2006. Thiazopyr and thyroid disruption: case study within the context of the 2006 IPCS Human Relevance Framework for analysis of a cancer mode of action. *Crit Rev Toxicol* 36(10):793–801, PMID: 17118729, <https://doi.org/10.1080/10408440600975242>.
- Dentice M, Marsili A, Zavacki A, Larsen PR, Salvatore D. 2013. The deiodinases and the control of intracellular thyroid hormone signaling during cellular differentiation. *Biochim Biophys Acta* 1830(7):3937–3945, PMID: 22634734, <https://doi.org/10.1016/j.bbagen.2012.05.007>.
- Denver RJ. 1998. The molecular basis of thyroid hormone-dependent central nervous system remodeling during amphibian metamorphosis. *Comp Biochem Physiol C Pharmacol Toxicol Endocrinol* 119(3):219–228, PMID: 9826995, [https://doi.org/10.1016/S0742-8413\(98\)00011-5](https://doi.org/10.1016/S0742-8413(98)00011-5).

- DeVito M, Biegel L, Brouwer A, Brown S, Brucker-Davis F, Cheek AO, et al. 1999. Screening methods for thyroid hormone disruptors. *Environ Health Perspect* 107(5):407–415, PMID: 10210697, <https://doi.org/10.1289/ehp.99107407>.
- Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, et al. 2009. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. *Endocr Rev* 30(4):293–342, PMID: 19502515, <https://doi.org/10.1210/er.2009-0002>.
- Dickson PW, Howlett GJ, Schreiber G. 1985. Rat transthyretin (prealbumin). Molecular cloning, nucleotide sequence, and gene expression in liver and brain. *J Biol Chem* 260(13):8214–8219, PMID: 3839240.
- Divi RL, Doerge DR. 1996. Inhibition of thyroid peroxidase by dietary flavonoids. *Chem Res Toxicol* 9(1):16–23, PMID: 8924586, <https://doi.org/10.1021/tx950076m>.
- Dix DJ, Houck KA, Martin MT, Richard AM, Setzer RW, Kavlock RJ. 2007. The ToxCast program for prioritizing toxicity testing of environmental chemicals. *Toxicol Sci* 95(1):5–12, PMID: 16963515, <https://doi.org/10.1093/toxsci/kfl103>.
- Doerge DR, Chang HC, Divi RL, Churchwell MI. 1998. Mechanism for inhibition of thyroid peroxidase by leucomalachite green. *Chem Res Toxicol* 11(9):1098–1104, PMID: 9760285, <https://doi.org/10.1021/bx970226o>.
- Dong H, Wade MG. 2017. Application of a nonradioactive assay for high throughput screening for inhibition of thyroid hormone uptake via the transmembrane transporter MCT8. *Toxicol In Vitro* 40:234–242, PMID: 28119167, <https://doi.org/10.1016/j.tiv.2017.01.014>.
- Dong H, Yauk CL, Rowan-Carroll A, You S-H, Zoeller RT, Lambert I, et al. 2009. Identification of thyroid hormone receptor binding sites and target genes using ChIP-on-chip in developing mouse cerebellum. *PLoS One* 4(2):e4610, PMID: 19240802, <https://doi.org/10.1371/journal.pone.0004610>.
- Dupré SM, Guissouma H, Flamant F, Seugnet I, Scanlan TS, Baxter JD, et al. 2004. Both thyroid hormone receptor (TR) β 1 and TR β 2 isoforms contribute to the regulation of hypothalamic *thyrotropin-releasing hormone*. *Endocrinology* 145(5):2337–2345, PMID: 14726446, <https://doi.org/10.1210/en.2003-1209>.
- Dussault JH, Ruel J. 1987. Thyroid hormones and brain development. *Annu Rev Physiol* 49:321–324, PMID: 3551803, <https://doi.org/10.1146/annurev.ph.49.030187.001541>.
- ECHA (European Chemicals Agency). 2016. *New Approach Methodologies in Regulatory Science*. Proceedings of a Scientific Workshop, 19–20 April 2016 2016, Helsinki, Finland. https://echa.europa.eu/documents/10162/22816069/scientific_ws_proceedings_en.pdf/a2087434-0407-4705-9057-95d9c2c2cc57 [accessed 5 October 2018].
- Engel S, Skoumbourdis AP, Childress J, Neumann S, Deschamps JR, Thomas CJ, et al. 2008. A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists. *J Am Chem Soc* 130(15):5115–5123, PMID: 18357984, <https://doi.org/10.1021/ja077620l>.
- EU. 2017. *Supporting the Organisation of a Workshop on Thyroid Disruption—Final Report*. European Commission, Framework Contract ENV.A.3/FRA/2014/0029 on implementation of the Community strategy on Endocrine Disrupters. <https://publications.europa.eu/en/publication-detail/-/publication/472d2c88-a8b1-11e7-837e-01aa75ed71a1/language-en> [accessed 15 July 2018].
- EU Science Hub. 2017. European drive to validate in vitro methods for the detection of thyroid disruptors. *EU Science Hub*. News and Events section. 4 July 2017. <https://ec.europa.eu/jrc/en/science-update/vitro-methods-detection-thyroid-disruptors> [accessed 1 August 2018].
- Ferreira ACF, Lisboa PC, Oliveira KJ, Lima LP, Barros IA, Carvalho DP. 2002. Inhibition of thyroid type 1 deiodinase activity by flavonoids. *Food Chem Toxicol* 40(7):913–917, PMID: 12065212, [https://doi.org/10.1016/S0278-6915\(02\)00064-9](https://doi.org/10.1016/S0278-6915(02)00064-9).
- Finken MJ, van Eijssden M, Loomans EM, Vrijkotte TG, Rotteveel J. 2013. Maternal hypothyroxinemia in early pregnancy predicts reduced performance in reaction time tests in 5- to 6-year-old offspring. *J Clin Endocrinol Metab* 98(4):1417–1426, PMID: 23408575, <https://doi.org/10.1210/jc.2012-3389>.
- Fort DJ, Rogers RL, Morgan LA, Miller MF, Clark PA, White JA, et al. 2000. Preliminary validation of a short-term morphological assay to evaluate adverse effects on amphibian metamorphosis and thyroid function using *Xenopus laevis*. *J Appl Toxicol* 20(5):419–425, PMID: 11139173, [https://doi.org/10.1002/1099-1263\(200009/10\)20:5<419::AID-JAT708>3.0.CO;2-A](https://doi.org/10.1002/1099-1263(200009/10)20:5<419::AID-JAT708>3.0.CO;2-A).
- Francis GL, Rennert OM. 1980. Correlation of plasma propylthiouracil levels with inhibition of thyroid hormone synthesis in the rat. *Metabolism* 29(5):410–414, PMID: 7374447, [https://doi.org/10.1016/0026-0495\(80\)90164-x](https://doi.org/10.1016/0026-0495(80)90164-x).
- Freitas J, Cano P, Craig-Veit C, Goodson ML, Furlow JD, Murk AJ. 2011. Detection of thyroid hormone receptor disruptors by a novel stable *in vitro* reporter gene assay. *Toxicol In Vitro* 25(1):257–266, PMID: 20732405, <https://doi.org/10.1016/j.tiv.2010.08.013>.
- Freitas J, Miller N, Mengeling BJ, Xia M, Huang R, Houck K, et al. 2014. Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform. *Curr Chem Genom Transl Med* 8:36–46, PMID: 24772387, <https://doi.org/10.2174/2213988501408010036>.
- Friesema ECH, Ganguly S, Abdalla A, Fox JEM, Halestrap AP, Visser TJ. 2003. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. *J Biol Chem* 278(41):40128–40135, PMID: 12871948, <https://doi.org/10.1074/jbc.M300909200>.
- Fu L, Das B, Matsuuwa K, Fujimoto K, Heimeier RA, Shi Y-B. 2017. Genome-wide identification of thyroid hormone receptor targets in the remodeling intestine during *Xenopus tropicalis* metamorphosis. *Sci Rep* 7(1):6414, PMID: 28743885, <https://doi.org/10.1038/s41598-017-06679-x>.
- Galton VA, de Waard E, Parlour AF, St Germain DL, Hernandez A. 2014. Life without the iodothyronine deiodinases. *Endocrinology* 155(10):4081–4087, PMID: 24949664, <https://doi.org/10.1210/en.2014-1114>.
- Galton VA, Schneider MJ, Clark AS, St Germain DL. 2009. Life without thyroxine to 3,5,3'-triiodothyronine conversion: studies in mice devoid of the 5'-deiodinases. *Endocrinology* 150(6):2957–2963, PMID: 19196796, <https://doi.org/10.1210/en.2008-1572>.
- Galton VA, Wood ET, St Germain EA, Withrow CA, Aldrich G, St Germain GM, et al. 2007. Thyroid hormone homeostasis and action in the type 2 deiodinase-deficient rodent brain during development. *Endocrinology* 148(7):3080–3088, PMID: 17332058, <https://doi.org/10.1210/en.2006-1727>.
- Garcia-Reyero N, Habib T, Pirooznia M, Gust KA, Gong P, Warner C, et al. 2011. Conserved toxic responses across divergent phylogenetic lineages: a meta-analysis of the neurotoxic effects of RDX among multiple species using toxicogenomics. *Ecotoxicology* 20(3):580–594, PMID: 21516383, <https://doi.org/10.1007/s10646-011-0623-3>.
- Gauger KJ, Giera S, Sharlin DS, Bansal R, Iannacone E, Zoeller RT. 2007. Polychlorinated biphenyls 105 and 118 form thyroid hormone receptor agonists after cytochrome P4501A1 activation in rat pituitary GH3 cells. *Environ Health Perspect* 115(11):1623–1630, PMID: 18007995, <https://doi.org/10.1289/ehp.10328>.
- Gentilcore D, Porreca I, Rizzo F, Ganbaatar E, Carchia E, Mallardo M, et al. 2013. Bisphenol A interferes with thyroid specific gene expression. *Toxicology* 304:21–31, PMID: 23238275, <https://doi.org/10.1016/j.tox.2012.12.001>.
- Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, et al. 2008. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. *Endocr Rev* 29(7):898–938, PMID: 18815314, <https://doi.org/10.1210/er.2008-0019>.
- Gershengorn MC, Neumann S. 2012. Update in TSH receptor agonists and antagonists. *J Clin Endocrinol Metab* 97(12):4287–4292, PMID: 23019348, <https://doi.org/10.1210/jc.2012-3080>.
- Ghassabian A, Henrichs J, Tiemeier H. 2014. Impact of mild thyroid hormone deficiency in pregnancy on cognitive function in children: lessons from the Generation R Study. *Best Pract Res Clin Endocrinol Metab* 28(2):221–232, PMID: 24629863, <https://doi.org/10.1016/j.beem.2013.04.008>.
- Gilbert ME. 2011. Impact of low-level thyroid hormone disruption induced by propylthiouracil on brain development and function. *Toxicol Sci* 124(2):432–445, PMID: 21964421, <https://doi.org/10.1093/toxsci/kfr244>.
- Gilbert ME, Goodman JH, Gomez J, Johnstone AFM, Ramos RL. 2017. Adult hippocampal neurogenesis is impaired by transient and moderate developmental thyroid hormone disruption. *Neurotoxicology* 59:9–21, PMID: 28048979, <https://doi.org/10.1016/j.neuro.2016.12.009>.
- Gilbert ME, Hedge JM, Valentini-Blasini L, Blount BC, Kannan K, Tietge J, et al. 2013. An animal model of marginal iodine deficiency during development: the thyroid axis and neurodevelopmental outcome. *Toxicol Sci* 132(1):177–195, PMID: 23288053, <https://doi.org/10.1093/toxsci/kfs335>.
- Gilbert ME, Sanchez-Huerta K, Wood C. 2016. Mild thyroid hormone insufficiency during development compromises activity-dependent neuroplasticity in the hippocampus of adult male rats. *Endocrinology* 157(2):774–787, PMID: 26606422, <https://doi.org/10.1210/en.2015-1643>.
- Gilbert ME, Sui L. 2008. Developmental exposure to perchlorate alters synaptic transmission in hippocampus of the adult rat. *Environ Health Perspect* 116(6):752–760, PMID: 18560531, <https://doi.org/10.1289/ehp.11089>.
- Gilbert M, Zoeller RT. 2010. Thyroid hormones—impact on the developing brain: possible mechanisms of neurotoxicity. In: *Neurotoxicology*. Harry GJ, Tillson HA, eds. Boca Raton, FL: CRC Press, 79–111.
- Goldey ES, Kehn LS, Lau C, Rehner GL, Crofton KM. 1995. Developmental exposure to polychlorinated biphenyls (Aroclor 1254) reduces circulating thyroid hormone concentrations and causes hearing deficits in rats. *Toxicol Appl Pharmacol* 135(1):77–88, PMID: 7482542, <https://doi.org/10.1006/taap.1995.1210>.
- Goleman WL, Carr JA, Anderson TA. 2002. Environmentally relevant concentrations of ammonium perchlorate inhibit thyroid function and alter sex ratios in developing *Xenopus laevis*. *Environ Toxicol Chem* 21(3):590–597, PMID: 11878472, <https://doi.org/10.1002/etc.5620210318>.
- Goodman JH, Gilbert ME. 2007. Modest thyroid hormone insufficiency during development induces a cellular malformation in the corpus callosum: a model of cortical dysplasia. *Endocrinology* 148(6):2593–2597, PMID: 17317780, <https://doi.org/10.1210/en.2006-1276>.

- Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, et al. 2015. EDC-2: the Endocrine Society's second scientific statement on endocrine-disrupting chemicals. *Endocr Rev* 36(6):E1–E150, PMID: 26544531, <https://doi.org/10.1210/en.2015-1010>.
- Grommen SVH, Iwasawa A, Beck V, Darras VM, De Groef B. 2011. Ontogenetic expression profiles of thyroid-specific genes in embryonic and hatching chicks. *Domest Anim Endocrinol* 40(1):10–18, PMID: 20926227, <https://doi.org/10.1016/j.domanied.2010.08.002>.
- Grøntved L, Waterfall JJ, Kim DW, Baek S, Sung M-H, Zhao L, et al. 2015. Transcriptional activation by the thyroid hormone receptor through ligand-dependent receptor recruitment and chromatin remodelling. *Nat Commun* 6:7048, PMID: 25916672, <https://doi.org/10.1038/ncomms8048>.
- Guadaño-Ferraz A, Obregón MJ, St Germain DL, Bernal J. 1997. The type 2 iodothyronine deiodinase is expressed primarily in glial cells in the neonatal rat brain. *Proc Natl Acad Sci U S A* 94(19):10391–10396, PMID: 9294221, <https://doi.org/10.1073/pnas.94.19.10391>.
- Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, et al. 1999. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *N Engl J Med* 341(8):549–555, PMID: 10451459, <https://doi.org/10.1056/NEJM199908193410801>.
- Haggard DE, Karmaus AL, Martin MT, Judson RS, Setzer RW, Paul Friedman K. 2018a. High-throughput H295R steroidogenesis assay: utility as an alternative and a statistical approach to characterize effects on steroidogenesis. *Toxicol Sci* 162(2):509–534, PMID: 29216406, <https://doi.org/10.1093/toxsci/kfx274>.
- Haggard DE, Noyes PD, Waters KM, Tanguay RL. 2018b. Transcriptomic and phenotypic profiling in developing zebrafish exposed to thyroid hormone receptor agonists. *Reprod Toxicol* 77:80–93, PMID: 29458080, <https://doi.org/10.1016/j.reprotox.2018.02.006>.
- Haines C, Chatham LR, Vardy A, Elcombe CR, Foster JR, Lake BG. 2018. Comparison of the hepatic and thyroid gland effects of sodium phenobarbital in wild type and constitutive androstanone receptor (CAR) knockout rats and pregnenolone-16 α -carbonitrile in wild type and pregnane X receptor (PXR) knockout rats. *Toxicology* 400–401:20–27, PMID: 29548889, <https://doi.org/10.1016/j.tox.2018.03.002>.
- Hallgren S, Darnerud PO. 2002. Polybrominated diphenyl ethers (PBDEs), polychlorinated biphenyls (PCBs) and chlorinated paraffins (CPs) in rats—testing interactions and mechanisms for thyroid hormone effects. *Toxicology* 177(2–3):227–243, PMID: 12135626, [https://doi.org/10.1016/S0300-483X\(02\)00222-6](https://doi.org/10.1016/S0300-483X(02)00222-6).
- Hallinger DR, Murr AS, Buckalew AR, Simmons SO, Stoker TE, Laws SC. 2017. Development of a screening approach to detect thyroid disrupting chemicals that inhibit the human sodium iodide symporter (NIS). *Toxicol In Vitro* 40:66–78, PMID: 27979590, <https://doi.org/10.1016/j.tiv.2016.12.006>.
- Hamers T, Kamstra JH, Sonneveld E, Murk AJ, Kester MHA, Andersson PL, et al. 2006. *In vitro* profiling of the endocrine-disrupting potency of brominated flame retardants. *Toxicol Sci* 92(1):157–173, PMID: 16601080, <https://doi.org/10.1093/toxsci/kfj187>.
- Harms PJ, Tu GF, Richardson SJ, Aldred AR, Jaworowski A, Schreiber G. 1991. Transthyretin (prealbumin) gene expression in choroid plexus is strongly conserved during evolution of vertebrates. *Comp Biochem Phys B* 99(1):239–249, PMID: 1959330, [https://doi.org/10.1016/0305-0491\(91\)90035-C](https://doi.org/10.1016/0305-0491(91)90035-C).
- Hassan I, El-Masri H, Kosian PA, Ford J, Degitz SJ, Gilbert ME. 2017. Neurodevelopment and thyroid hormone synthesis inhibition in the rat: quantitative understanding within the adverse outcome pathway framework. *Toxicol Sci* 160(1):57–73, PMID: 28973696, <https://doi.org/10.1093/toxsci/kfx163>.
- He G, Tsutsumi T, Zhao B, Baston DS, Zhao J, Heath-Pagliuso S, et al. 2011. Third-generation Ah receptor-responsive luciferase reporter plasmids: amplification of dioxin-responsive elements dramatically increases CALUX bioassay sensitivity and responsiveness. *Toxicol Sci* 123(2):511–522, PMID: 21775728, <https://doi.org/10.1093/toxsci/kfr189>.
- Hedge JM, DeVito MJ, Crofton KM. 2009. *In vivo* acute exposure to polychlorinated biphenyls: effects on free and total thyroxine in rats. *Int J Toxicol* 28(5):382–391, PMID: 19815845, <https://doi.org/10.1177/1091581809344631>.
- Hernandez A, Quignodon L, Martinez ME, Flamant F, St Germain DL. 2010. Type 3 deiodinase deficiency causes spatial and temporal alterations in brain T₃ signaling that are dissociated from serum thyroid hormone levels. *Endocrinology* 151(11):5550–5558, PMID: 20719855, <https://doi.org/10.1210/en.2010-0450>.
- Heuer H, Maier MK, Iden S, Mittag J, Friesema ECH, Visser TJ, et al. 2005. The monocarboxylate transporter 8 linked to human psychomotor retardation is highly expressed in thyroid hormone-sensitive neuron populations. *Endocrinology* 146(4):1701–1706, PMID: 15661862, <https://doi.org/10.1210/en.2004-1179>.
- Hoffmann S, de Vries RBM, Stephens ML, Beck NB, Dirven H, Fowle JR III, et al. 2017. A primer on systematic reviews in toxicology. *Arch Toxicol* 91(7):2551–2575, PMID: 28501917, <https://doi.org/10.1007/s00204-017-1980-3>.
- Hofmann PJ, Schomburg L, Köhrle J. 2009. Interference of endocrine disruptors with thyroid hormone receptor-dependent transactivation. *Toxicol Sci* 110(1):125–137, PMID: 19403856, <https://doi.org/10.1093/toxsci/kfp086>.
- Hood A, Allen ML, Liu Y, Liu J, Klaassen CD. 2003. Induction of T₄ UDP-GT activity, serum thyroid stimulating hormone, and thyroid follicular cell proliferation in mice treated with microsomal enzyme inducers. *Toxicol Appl Pharmacol* 188(1):6–13, PMID: 12668117, [https://doi.org/10.1016/S0041-008X\(02\)00071-6](https://doi.org/10.1016/S0041-008X(02)00071-6).
- Hood A, Klaassen CD. 2000. Effects of microsomal enzyme inducers on outer-ring deiodinase activity toward thyroid hormones in various rat tissues. *Toxicol Appl Pharm* 163(3):240–248, PMID: 10702363, <https://doi.org/10.1006/taap.1999.8883>.
- Hornung MW, Korte JJ, Olker JH, Denny JS, Knutsen C, Hartig PC, et al. 2018. Screening the ToxCast phase 1 chemical library for inhibition of deiodinase type 1 activity. *Toxicol Sci* 162(2):570–581, PMID: 29228274, <https://doi.org/10.1093/toxsci/kfx279>.
- Hornung MW, Kosian PA, Haselman JT, Korte JJ, Challis K, Macherla C, et al. 2015. *In vitro*, *ex vivo*, and *in vivo* determination of thyroid hormone modulating activity of benzothiazoles. *Toxicol Sci* 146(2):254–264, PMID: 25953703, <https://doi.org/10.1093/toxsci/kfv090>.
- Houck B, Bone A, Paul-Friedman K, Hsu C, Sakamuru S, Xia M, et al. 2018. Screening the 10K Tox21 chemical library for thyroid hormone receptor modulators [Abstract #1844]. In: *SOT Annual Meeting*, 11–15 March 2018, San Antonio, TX: Society of Toxicology.
- Houten SM, Chen J, Belpoggi F, Manservisi F, Sánchez-Guijo A, Wudy SA, et al. 2016. Changes in the metabolome in response to low-dose exposure to environmental chemicals used in personal care products during different windows of susceptibility. *PLoS One* 11(7):e0159919, PMID: 27467775, <https://doi.org/10.1371/journal.pone.0159919>.
- Huang R, Xia M, Cho MH, Sakamuru S, Shinn P, Houck KA, et al. 2011. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. *Environ Health Perspect* 119(8):1142–1148, PMID: 21543282, <https://doi.org/10.1289/ehp.100295>.
- Huang R, Xia M, Sakamuru S, Zhao J, Shahane SA, Attene-Ramos M, et al. 2016. Modelling the Tox21 10 K chemical profiles for *in vivo* toxicity prediction and mechanism characterization. *Nat Commun* 7:10425, PMID: 26811972, <https://doi.org/10.1038/ncomms10425>.
- Huang SSY, Benskin JP, Chandramouli B, Butler H, Helbing CC, Cosgrove JR. 2016. Xenobiotics produce distinct metabolomic responses in zebrafish larvae (*Danio rerio*). *Environ Sci Technol* 50(12):6526–6535, PMID: 27232715, <https://doi.org/10.1021/es6001128>.
- Hurley PM. 1998. Mode of carcinogenic action of pesticides inducing thyroid follicular cell tumors in rodents. *Environ Health Perspect* 106(8):437–445, PMID: 9681970, <https://doi.org/10.1289/ehp.98106437>.
- Hytti OM, Portman MA. 2006. Molecular mechanisms of cross-talk between thyroid hormone and peroxisome proliferator activated receptors: focus on the heart. *Cardiovasc Drugs Ther* 20(6):463–469, PMID: 17171294, <https://doi.org/10.1007/s10557-006-0643-z>.
- ICCVAM (Interagency Coordinating Committee on the Validation of Alternative Methods). 2018. *A Strategic Roadmap for Establishing New Approaches to Evaluate the Safety of Chemicals and Medical Products in the United States*. Washington, DC: National Toxicology Program, ICCVAM. <https://ntp.niehs.nih.gov/pubhealth/evalatm/natl-strategy/index.html> [accessed 2 October 2018].
- Ishihara A, Nishiyama N, Sugiyama S-I, Yamauchi K. 2003. The effect of endocrine disrupting chemicals on thyroid hormone binding to Japanese quail transthyretin and thyroid hormone receptor. *Gen Comp Endocrinol* 134(1):36–43, PMID: 13129501, [https://doi.org/10.1016/s0016-6480\(03\)00197-7](https://doi.org/10.1016/s0016-6480(03)00197-7).
- Jarque S, Fetter E, Veneman WJ, Spaink HP, Perivali R, Strähle U, et al. 2018. An automated screening method for detecting compounds with goitrogenic activity using transgenic zebrafish embryos. *PLoS One* 13(8):e0203087, PMID: 30157258, <https://doi.org/10.1371/journal.pone.0203087>.
- Ji C, Jin X, He JY, Yin Z. 2012. Use of TSH β :EGFP transgenic zebrafish as a rapid *in vivo* model for assessing thyroid-disrupting chemicals. *Toxicol Appl Pharmacol* 262(2):149–155, PMID: 22571824, <https://doi.org/10.1016/j.taap.2012.04.029>.
- Johnson CH, Patterson AD, Idle JR, Gonzalez FJ. 2012. Xenobiotic metabolomics: major impact on the metabolome. *Annu Rev Pharmacol Toxicol* 52:37–56, PMID: 21819238, <https://doi.org/10.1146/annurev-pharmtox-010611-134748>.
- Jomaa B, Aarts J, de Haan LHJ, Peijnenburg A, Bovee TFH, Murk AJ, et al. 2013. *In vitro* pituitary and thyroid cell proliferation assays and their relevance as alternatives to animal testing. *ALTEX* 30(3):293–307, PMID: 23861076, <https://doi.org/10.14573/altex.2013.3.293>.
- Judson RS, Houck KA, Kaylock RJ, Knudsen TB, Martin MT, Mortensen HM, et al. 2010. *In vitro* screening of environmental chemicals for targeted testing prioritization: the ToxCast project. *Environ Health Perspect* 118(4):485–492, PMID: 20368123, <https://doi.org/10.1289/ehp.0901392>.
- Judson RS, Houck KA, Watt ED, Thomas RS. 2017. On selecting a minimal set of *in vitro* assays to reliably determine estrogen agonist activity. *Regul Toxicol Pharmacol* 91:39–49, PMID: 28993267, <https://doi.org/10.1016/j.yrtph.2017.09.022>.
- Judson RS, Magpantay FM, Chickaramane V, Haskell C, Tania N, Taylor J, et al. 2015. Integrated model of chemical perturbations of a biological pathway using

- 18 *in vitro* high-throughput screening assays for the estrogen receptor. *Toxicol Sci* 148(1):137–154, PMID: 26272952, <https://doi.org/10.1093/toxsci/kfv168>.
- Juge-Aubry CE, Gorla-Bajszczak A, Pernin A, Lemberger T, Wahli W, Burger AG, et al. 1995. Peroxisome proliferator-activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X receptor. Possible role of a leucine zipper-like heptad repeat. *J Biol Chem* 270(30):18117–18122, PMID: 7629123, <https://doi.org/10.1074/jbc.270.30.18117>.
- Karmaus AL, Toole CM, Filer DL, Lewis KC, Martin MT. 2016. High-throughput screening of chemical effects on steroidogenesis using H295R human adrenocortical carcinoma cells. *Toxicol Sci* 150(2):323–332, PMID: 26781511, <https://doi.org/10.1093/toxsci/kfw002>.
- Kato Y, Suzuki H, Haraguchi K, Ikushiro S, Ito Y, Uchida S, et al. 2010. A possible mechanism for the decrease in serum thyroxine level by phenobarbital in rodents. *Toxicol Appl Pharmacol* 249(3):238–246, PMID: 20932986, <https://doi.org/10.1016/j.taap.2010.09.024>.
- Kavlock RJ, Ankley G, Blancato J, Breen M, Conolly R, Dix D, et al. 2008. Computational toxicology—a state of the science mini review. *Toxicol Sci* 103(1):14–27, PMID: 18065772, <https://doi.org/10.1093/toxsci/kfm297>.
- Kitamura S, Jinno N, Ohta S, Kuroki H, Fujimoto N. 2002. Thyroid hormonal activity of the flame retardants tetrabromobisphenol A and tetrachlorobisphenol A. *Biochem Biophys Res Commun* 293(1):554–559, PMID: 12054637, [https://doi.org/10.1016/S0006-291X\(02\)00262-0](https://doi.org/10.1016/S0006-291X(02)00262-0).
- Kitamura S, Jinno N, Suzuki T, Sugihara K, Ohta S, Kuroki H, et al. 2005. Thyroid hormone-like and estrogenic activity of hydroxylated PCBs in cell culture. *Toxicology* 208(3):377–387, PMID: 15695023, <https://doi.org/10.1016/j.tox.2004.11.037>.
- Klaassen CD, Hood AM. 2001. Effects of microsomal enzyme inducers on thyroid follicular cell proliferation and thyroid hormone metabolism. *Toxicol Pathol* 29(1):34–40, PMID: 11215682, <https://doi.org/10.1080/019262301301418838>.
- Kleinsteuer NC, Ceger P, Watt ED, Martin M, Houck K, Browne P, et al. 2017. Development and validation of a computational model for androgen receptor activity. *Chem Res Toxicol* 30(4):946–964, PMID: 27933809, <https://doi.org/10.1021/acs.chemrestox.6b00347>.
- Knudsen TB, Houck KA, Sipes NS, Singh AV, Judson RS, Martin MT, et al. 2011. Activity profiles of 309 ToxCast™ chemicals evaluated across 292 biochemical targets. *Toxicology* 282(1–2):1–15, PMID: 21251949, <https://doi.org/10.1016/j.tox.2010.12.010>.
- Köhrl J. 1999. Local activation and inactivation of thyroid hormones: the deiodinase family. *Mol Cell Endocrinol* 151(1–2):103–119, PMID: 10411325, [https://doi.org/10.1016/S0303-7207\(99\)00040-4](https://doi.org/10.1016/S0303-7207(99)00040-4).
- Köhrl J. 2008. Environment and endocrinology: the case of thyroidology. *Ann Endocrinol (Paris)* 69(2):116–122, PMID: 18440490, <https://doi.org/10.1016/j.ando.2008.02.008>.
- Kojima H, Takeuchi S, Uramaru N, Sugihara K, Yoshida T, Kitamura S. 2009. Nuclear hormone receptor activity of polybrominated diphenyl ethers and their hydroxylated and methoxylated metabolites in transactivation assays using Chinese hamster ovary cells. *Environ Health Perspect* 117(8):1210–1218, PMID: 19672399, <https://doi.org/10.1289/ehp.0900753>.
- Kondo T, Ikenaka Y, Nakayama SMM, Kawai YK, Mizukawa H, Mitani Y, et al. 2017. Uridine diphosphate-glucuronosyltransferase (UGT) 2B subfamily interspecies differences in carnivores. *Toxicol Sci* 158(1):90–100, PMID: 28453659, <https://doi.org/10.1093/toxsci/kfx072>.
- Konno Y, Negishi M, Kodama S. 2008. The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. *Drug Metab Pharmacokinet* 23(1):8–13, PMID: 18305370, <https://doi.org/10.2133/dmpk.23.8>.
- Korevaar TI, Muetzel R, Medici M, Chaker L, Jaddoe VW, de Rijke YB, et al. 2016. Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based prospective cohort study. *Lancet Diabetes Endocrinol* 4(1):35–43, PMID: 26497402, [https://doi.org/10.1016/S2213-8587\(15\)00327-7](https://doi.org/10.1016/S2213-8587(15)00327-7).
- Kyono Y, Subramani A, Ramadoss P, Hollenberg AN, Bonett RM, Denver RJ. 2016. Liganded thyroid hormone receptors transactivate the DNA methyltransferase 3a gene in mouse neuronal cells. *Endocrinology* 157(9):3647–3657, PMID: 27387481, <https://doi.org/10.1210/en.2015-1529>.
- Lake AD, Wood CE, Bhat VS, Chorley BN, Carswell GK, Sey YM, et al. 2016. Dose and effect thresholds for early key events in a PPARα-mediated mode of action. *Toxicol Sci* 149(2):312–325, PMID: 26519955, <https://doi.org/10.1093/toxsci/kfv236>.
- LaLone CA, Villeneuve DL, Burgoon LD, Russom CL, Helgen HW, Berninger JP, et al. 2013. Molecular target sequence similarity as a basis for species extrapolation to assess the ecological risk of chemicals with known modes of action. *Aquat Toxicol* 144–145:141–154, PMID: 24177217, <https://doi.org/10.1016/j.aquatox.2013.09.004>.
- Landers KA, McKinnon BD, Li HK, Subramaniam VN, Mortimer RH, Richard K. 2009. Carrier-mediated thyroid hormone transport into placenta by placental transthyretin. *J Clin Endocrinol Metab* 94(7):2610–2616, PMID: 19401362, <https://doi.org/10.1210/jc.2009-0048>.
- Lans MC, Spiertz C, Brouwer A, Koeman JH. 1994. Different competition of thyroxine-binding to transthyretin and thyroxine-binding globulin by hydroxy-PCBS, PCDDs and PCDFs. *Eur J Pharmacol* 270(2–3):129–136, PMID: 8039542, [https://doi.org/10.1016/0926-6917\(94\)90054-X](https://doi.org/10.1016/0926-6917(94)90054-X).
- Larson B, Kelts JL, Banks P, Cali JJ. 2011. Automation and miniaturization of the bioluminescent UGT-Glo assay for screening of UDP-glucuronosyltransferase inhibition by various compounds. *J Lab Autom* 16(1):38–46, PMID: 21609684, <https://doi.org/10.1016/j.jala.2010.05.005>.
- Lasley SM, Gilbert ME. 2011. Developmental thyroid hormone insufficiency reduces expression of brain-derived neurotrophic factor (BDNF) in adults but not in neonates. *Neurotoxicol Teratol* 33(4):464–472, PMID: 21530650, <https://doi.org/10.1016/j.ntt.2011.04.001>.
- Lecat-Guillet N, Merer G, Lopez R, Pourcher T, Rousseau B, Ambroise Y. 2008. Small-molecule inhibitors of sodium iodide symporter function. *Chembiochem* 9(6):889–895, PMID: 18307189, <https://doi.org/10.1002/cbic.200700682>.
- Lee H-S, Kang Y, Tae K, Bae G-U, Park JY, Cho YH, et al. 2018. Proteomic biomarkers for bisphenol A—early exposure and women's thyroid cancer. *Cancer Res Treat* 50(1):111–117, PMID: 28279065, <https://doi.org/10.4143/crt.2017.001>.
- Lewandowski TA, Seeley MR, Beck BD. 2004. Interspecies differences in susceptibility to perturbation of thyroid homeostasis: a case study with perchlorate. *Regul Toxicol Pharmacol* 39(3):348–362, PMID: 15135213, <https://doi.org/10.1016/j.yrtph.2004.03.002>.
- Lu C, Cheng SY. 2010. Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors. *J Mol Endocrinol* 44(3):143–154, PMID: 19741045, <https://doi.org/10.1677/JME-09-0107>.
- Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, et al. 2003. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. *J Biol Chem* 278(19):17277–17283, PMID: 12611900, <https://doi.org/10.1074/jbc.M300138200>.
- Marchesini GR, Meimardou A, Haasnoot W, Meulenbergh E, Albertus F, Mizuguchi M, et al. 2008. Biosensor discovery of thyroxine transport disrupting chemicals. *Toxicol Appl Pharm* 232(1):150–160, PMID: 18647617, <https://doi.org/10.1016/j.taap.2008.06.014>.
- Marchesini GR, Meulenbergh E, Haasnoot W, Mizuguchi M, Irth H. 2006. Biosensor recognition of thyroid-disrupting chemicals using transport proteins. *Anal Chem* 78(4):1107–1114, PMID: 16478101, <https://doi.org/10.1021/ac051399>.
- Markossian S, Guyot R, Richard S, Teixeira M, Aguilera N, Bouchet M, et al. 2018. CRISPR/Cas9 editing of the mouse *Thra* gene produces models with variable resistance to thyroid hormone. *Thyroid* 28(1):139–150, PMID: 29205102, <https://doi.org/10.1089/thy.2017.0389>.
- Martignoni M, Groothuis GM, de Kanter R. 2006. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. *Expert Opin Drug Metab Toxicol* 2(6):875–894, PMID: 17125407, <https://doi.org/10.1517/17425255.2.6.875>.
- Martin MT, Dix DJ, Judson RS, Kavlock RJ, Reif DM, Richard AM, et al. 2010. Impact of environmental chemicals on key transcription regulators and correlation to toxicity end points within EPA's ToxCast program. *Chem Res Toxicol* 23(3):578–590, PMID: 20143881, <https://doi.org/10.1021/tx900325g>.
- McClain RM, Posch RC, Bosakowski T, Armstrong JM. 1988. Studies on the mode of action for thyroid gland tumor promotion in rats by phenobarbital. *Toxicol Appl Pharmacol* 94(2):254–265, PMID: 3388422, [https://doi.org/10.1016/0041-008x\(88\)90267-0](https://doi.org/10.1016/0041-008x(88)90267-0).
- McNabb FMA, Jang DA, Larsen CT. 2004. Does thyroid function in developing birds adapt to sustained ammonium perchlorate exposure? *Toxicol Sci* 82(1):106–113, PMID: 15310858, <https://doi.org/10.1093/toxsci/kfh247>.
- Meerts I, van Zanden JJ, Luijks EAC, van Leeuwen-Bol I, Marsh G, Jakobsson E, et al. 2000. Potent competitive interactions of some brominated flame retardants and related compounds with human transthyretin in vitro. *Toxicol Sci* 56(1):95–104, PMID: 10869457, <https://doi.org/10.1093/toxsci/56.1.95>.
- Mendel CM. 1989. The free hormone hypothesis: a physiologically based mathematical model. *Endocr Rev* 10(3):232–274, PMID: 2673754, <https://doi.org/10.1210/edrv-10-3-232>.
- Miller MD, Crofton KM, Rice DC, Zoeller RT. 2009. Thyroid-disrupting chemicals: interpreting upstream biomarkers of adverse outcomes. *Environ Health Perspect* 117(7):1033–1041, PMID: 19654909, <https://doi.org/10.1289/ehp.0800247>.
- Mol KA, Van der Geyten S, Kuhn ER, Darras VM. 1999. Effects of experimental hypo- and hyperthyroidism on iodothyronine deiodinases in Nile tilapia, *Oreochromis niloticus*. *Fish Physiol Biochem* 20(3):201–207, <https://doi.org/10.1023/A:1007739431710>.
- Moleti M, Di Bella B, Giorgianni G, Mancuso A, De Vivo A, Alibrandi A, et al. 2011. Maternal thyroid function in different conditions of iodine nutrition in pregnant women exposed to mild-moderate iodine deficiency: an observational study. *Clin Endocrinol (Oxf)* 74(6):762–768, PMID: 21521276, <https://doi.org/10.1111/j.1365-2265.2011.04007.x>.
- Montaño M, Cocco E, Guignard C, Marsh G, Hoffmann L, Bergman A, et al. 2012. New approaches to assess the transthyretin binding capacity of bioactivated

- thyroid hormone disruptors. *Toxicol Sci* 130(1):94–105, PMID: 22859314, <https://doi.org/10.1093/toxsci/kfs228>.
- Moriyama K, Tagami T, Akamizu T, Usui T, Saito M, Kanamoto N, et al. 2002. Thyroid hormone action is disrupted by bisphenol A as an antagonist. *J Clin Endocrinol Metab* 87(11):5185–5190, PMID: 12414890, <https://doi.org/10.1210/jc.2002-020209>.
- Morerale de Escobar G, Obregon MJ, Escobar del Rey F. 2000. Is neuropsychological development related to maternal hypothyroidism or to maternal hypothyroxinemia? *Clin Endocrinol Metab* 85(11):3975–3987, PMID: 11095417, <https://doi.org/10.1210/jcem.85.11.6961>.
- Morerale de Escobar G, Ares S, Berbel P, Obregon MJ, del Rey FE. 2008. The changing role of maternal thyroid hormone in fetal brain development. *Semin Perinatol* 32(6):380–386, PMID: 19007674, <https://doi.org/10.1053/j.semperi.2008.09.002>.
- Morerale de Escobar G, Obregon MJ, del Rey FE. 2004a. Maternal thyroid hormones early in pregnancy and fetal brain development. *Best Pract Res Clin Endocrinol Metab* 18(2):225–248, PMID: 15157838, [https://doi.org/10.1016/S1521-690X\(04\)00022-3](https://doi.org/10.1016/S1521-690X(04)00022-3).
- Morerale de Escobar G, Obregon MJ, Escobar del Rey F. 2004b. Role of thyroid hormone during early brain development. *Eur J Endocrinol* 151(Suppl 3):U25–U37, PMID: 15554884, <https://doi.org/10.1530/eje.0.151u025>.
- Morse DC, Groen D, Veerman M, van Amerongen CJ, Koeter HB, Smits van Prooijen AE, et al. 1993. Interference of polychlorinated biphenyls in hepatic and brain thyroid hormone metabolism in fetal and neonatal rats. *Toxicol Appl Pharmacol* 122(1):27–33, PMID: 8378931, <https://doi.org/10.1006/taap.1993.1168>.
- Mortimer RH, Landers KA, Balakrishnan B, Li H, Mitchell MD, Patel J, et al. 2012. Secretion and transfer of the thyroid hormone binding protein transthyretin by human placenta. *Placenta* 33(4):252–256, PMID: 22264585, <https://doi.org/10.1016/j.placenta.2012.01.006>.
- Murk AJ, Rijntjes E, Blaauwboer BJ, Clewell R, Crofton KM, Dingemans MML, et al. 2013. Mechanism-based testing strategy using *in vitro* approaches for identification of thyroid hormone disrupting chemicals. *Toxicol In Vitro* 27(4):1320–1346, PMID: 23453986, <https://doi.org/10.1016/j.tiv.2013.02.012>.
- National Academies of Sciences, Engineering, and Medicine. 2007. *Toxicity Testing in the 21st Century: A Vision and a Strategy*. Washington, DC: National Academies Press.
- National Academies of Sciences, Engineering, and Medicine. 2018. *Progress Toward Transforming the Integrated Risk Information System (IRIS) Program: A 2018 Evaluation*. Washington, DC: National Academies Press.
- Nebert DW, Gonzalez FJ. 1987. P450 genes: structure, evolution, and regulation. *Annu Rev Biochem* 56:945–993, PMID: 3304150, <https://doi.org/10.1146/annurev.bi.56.070187.004501>.
- Nelson KR, Schroeder AL, Ankley GT, Blackwell BR, Blanksma C, Degitz SJ, et al. 2016. Impaired anterior swim bladder inflation following exposure to the thyroid peroxidase inhibitor 2-mercaptopbenzothiazole part I: fathead minnow. *Aquat Toxicol* 173:192–203, PMID: 26852267, <https://doi.org/10.1016/j.aquatox.2015.12.024>.
- Neumann S, Huang WW, Titus S, Krause G, Kleinau G, Alberobello AT, et al. 2009. Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. *Proc Natl Acad Sci U S A* 106(30):12471–12476, PMID: 19592511, <https://doi.org/10.1073/pnas.0904506106>.
- Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, et al. 1998. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor- γ . *Nature* 395(6698):137–143, PMID: 9744270, <https://doi.org/10.1038/25931>.
- Noyes PD, Hinton DE, Stapleton HM. 2011. Accumulation and debromination of decabromodiphenyl ether (BDE-209) in juvenile fathead minnows (*Pimephales promelas*) induces thyroid disruption and liver alterations. *Toxicol Sci* 122(2):265–274, PMID: 21546348, <https://doi.org/10.1093/toxsci/kfr105>.
- Noyes PD, Lema SC, Macaulay LJ, Douglas NK, Stapleton HM. 2013. Low level exposure to the flame retardant BDE-209 reduces thyroid hormone levels and disrupts thyroid signaling in fathead minnows. *Environ Sci Technol* 47(17):10012–10021, PMID: 23899252, <https://doi.org/10.1021/es402650x>.
- NRC (National Research Council). 2005. *Health Implications of Perchlorate Ingestion*. Washington, DC: National Academies Press.
- O'Shaughnessy KL, Kosian PA, Ford JL, Oshiro WM, Degitz SJ, Gilbert ME. 2018a. Developmental thyroid hormone insufficiency induces a cortical brain malformation and learning impairments: a cross-fostering study. *Toxicol Sci* 163(1):101–115, PMID: 29385626, <https://doi.org/10.1093/toxsci/kfy016>.
- O'Shaughnessy KL, Wood CR, Ford RL, Kosian PA, Hotchkiss MG, Degitz SJ, et al. 2018b. Thyroid hormone disruption in the fetal and neonatal rat: predictive hormone measures and bioindicators of hormone action in the developing cortex. *Toxicol Sci* 166(1):163–179, PMID: 30085217, <https://doi.org/10.1093/toxsci/kfy190>.
- Obregon MJ, Ruiz de Oña C, Calvo R, Escobar del Rey F, Morerale de Escobar G. 1991. Outer ring iodothyronine deiodinases and thyroid hormone economy: responses to iodine deficiency in the rat fetus and neonate. *Endocrinology* 129(5):2663–2673, PMID: 1935795, <https://doi.org/10.1210/endo-129-5-2663>.
- OECD (Organisation for Economic Co-operation and Development). 2009. Test no. 441: Hershberger bioassay in rats: a short-term screening assay for (anti) androgenic properties. In: *OECD Guidelines for the Testing of Chemicals*, Section 4. Paris, France: OECD. <https://doi.org/10.1787/9789264076334-en> [accessed 20 September 2018].
- OECD. 2014. New scoping document on *in vitro* and *ex vivo* assays for the identification of modulators of thyroid hormone signaling. In: *OECD Environment, Health and Safety Publications Series on Testing and Assessment*. No. 207. ENV/JM/MONO(2014)23. Paris, France: OECD. [http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono\(2014\)23&doclanguage=en](http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono(2014)23&doclanguage=en) [accessed 20 September 2016].
- OECD. 2018a. Amphibian metamorphosis assay (AMA) (OECD TG 231). In: *Revised Guidance Document 150 on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption*. Paris, France: OECD. <https://doi.org/10.1787/9789264304741-8-en> [accessed 15 September 2018].
- OECD. 2018b. Combined chronic toxicity/carcinogenicity studies (OECD TG 451-3). In: *Revised Guidance Document 150 on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption*. Paris, France: OECD. <https://doi.org/10.1787/9789264304741-24-en> [accessed 15 September 2018].
- OECD. 2018c. Developmental neurotoxicity study (OECD TG 426). In: *Revised Guidance Document 150 on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption*. Paris, France: OECD. <https://doi.org/10.1787/9789264304741-27-en> [accessed 15 September 2018].
- OECD. 2018d. Extended one-generation reproductive toxicity study (EOGRTS) (OECD TG 443). In: *Revised Guidance Document 150 on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption*. Paris, France: OECD. <https://doi.org/10.1787/9789264304741-34-en> [accessed 15 September 2018].
- OECD. 2018e. Larval amphibian growth and development assay (LAGDA) (OECD TG 241). In: *Revised Guidance Document 150 on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption*. Paris, France: OECD. <https://doi.org/10.1787/9789264304741-15-en> [accessed 15 September 2018].
- OECD. 2018f. Prenatal developmental toxicity study (OECD TG 414). In: *Revised Guidance Document 150 on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption*. Paris, France: OECD. <https://doi.org/10.1787/9789264304741-26-en> [accessed 15 September 2018].
- OECD. 2018g. Repeated dose 28-day oral toxicity study in rodents (OECD TG 407). In: *Revised Guidance Document 150 on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption*. Paris, France: OECD. <https://doi.org/10.1787/9789264304741-22-en> [accessed 15 September 2018].
- OECD. 2018h. Repeated dose 90-day oral toxicity study in rodents (OECD TG 408). In: *Revised Guidance Document 150 on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption*. Paris, France: OECD. <https://doi.org/10.1787/9789264304741-23-en> [accessed 15 September 2018].
- OECD. 2018i. Reproduction/developmental toxicity screening test (OECD TG 421) and combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (OECD TG 422). In: *Revised Guidance Document 150 on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption*. Paris, France: OECD. <https://doi.org/10.1787/9789264304741-25-en> [accessed 15 September 2018].
- OECD. 2018j. *Revised guidance document 150 on standardised test guidelines for evaluating chemicals for endocrine disruption*. OECD Series on Testing and Assessment, No. 150. Paris, France: OECD. <https://doi.org/10.1787/9789264304741-en> [accessed 15 September 2018].
- OECD. 2018k. Two-generation reproduction toxicity study (OECD TG 416). In: *Revised Guidance Document 150 on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption*. Paris, France: OECD. <https://doi.org/10.1787/9789264304741-33-en> [accessed 15 September 2018].
- Ohara A, Yamada F, Fukuda T, Suzuki N, Sumida K. 2018. Specific alteration of gene expression profile in rats by treatment with thyroid toxicants that inhibit thyroid hormone synthesis. *J Appl Toxicol* 12:1529–1537, PMID: 30047161, <https://doi.org/10.1002/jat.3693>.
- Ohnhaus EE, Bürgi H, Burger A, Studer H. 1981. The effect of antipyrine, phenobarbital and rifampicin on thyroid hormone metabolism in man. *Eur J Clin Invest* 11(5):381–387, PMID: 680809, <https://doi.org/10.1111/j.1365-2362.1981.tb02000.x>.
- Olker JH, Haselman JT, Kosian PA, Donnay KG, Korte JJ, Blanksma C, et al. 2018. Evaluating iodide recycling inhibition as a novel molecular initiating event for thyroid axis disruption in amphibians. *Toxicol Sci* 166(2):318–331, PMID: 30137636, <https://doi.org/10.1093/toxsci/kfy203>.
- Olker JH, Korte JJ, Denny JS, Hartig PC, Cardon MC, Knutson CN, et al. 2019. Screening the ToxCast phase 1, phase 2, and e1k chemical libraries for inhibitors of iodothyronine deiodinases. *Toxicol Sci* 168(2):430–442, PMID: 30561685, <https://doi.org/10.1093/toxsci/kfy302>.
- Opitz R, Maquet E, Huiskens J, Antonica F, Trubiroha A, Pottier G, et al. 2012. Transgenic zebrafish illuminate the dynamics of thyroid morphogenesis and its relationship to cardiovascular development. *Dev Biol* 372(2):203–216, PMID: 23022354, <https://doi.org/10.1016/j.ydbio.2012.09.011>.

- Oppenheimer JH, Schwartz HL. 1997. Molecular basis of thyroid hormone-dependent brain development. *Endocr Rev* 18(4):462–475, PMID: 9267760, <https://doi.org/10.1210/edrv.18.4.0309>.
- Patel J, Landers K, Li H, Mortimer RH, Richard K. 2011. Thyroid hormones and fetal neurological development. *J Endocrinol* 209(1):1–8, PMID: 21212091, <https://doi.org/10.1530/JOE-10-0444>.
- Paul Friedman K, Watt ED, Hornung MW, Hedge JM, Judson RS, Crofton KM, et al. 2016. Tiered high-throughput screening approach to identify thyroperoxidase inhibitors within the ToxCast phase I and II chemical libraries. *Toxicol Sci* 151(1):160–180, PMID: 26884060, <https://doi.org/10.1093/toxsci/kfw034>.
- Paul Friedman K, Zhao J, Huang R, Xia M, Crofton KM, Houck KA. 2017. Screening the Tox21 10K library for thyroid stimulating hormone receptor agonist and antagonist activity [Abstract #3423]. In: *SOT Annual Meeting*, 12–16 March 2017, Baltimore, MD: Society of Toxicology.
- Paul KB, Hedge JM, Macherla C, Filer DL, Burgess E, Simmons SO, et al. 2013. Cross-species analysis of thyroperoxidase inhibition by xenobiotics demonstrates conservation of response between pig and rat. *Toxicology* 312:97–107, PMID: 23959146, <https://doi.org/10.1016/j.tox.2013.08.006>.
- Paul KB, Hedge JM, Rotroff DM, Hornung MW, Crofton KM, Simmons SO. 2014. Development of a thyroperoxidase inhibition assay for high-throughput screening. *Chem Res Toxicol* 27(3):387–399, PMID: 24383450, <https://doi.org/10.1021/tx400310w>.
- Paul KB, Thompson JT, Simmons SO, Vanden Heuvel JP, Crofton KM. 2013. Evidence for triclosan-induced activation of human and rodent xenobiotic nuclear receptors. *Toxicol In Vitro* 27(7):2049–2060, PMID: 23899473, <https://doi.org/10.1016/j.tiv.2013.07.008>.
- Perkins EJ, Ankley GT, Crofton KM, Garcia-Reyero N, LaLone CA, Johnson MS, et al. 2013. Current perspectives on the use of alternative species in human health and ecological hazard assessments. *Environ Health Perspect* 121(9):1002–1010, PMID: 23771518, <https://doi.org/10.1289/ehp.1306638>.
- Politi R, Rusyn I, Tropsha A. 2014. Prediction of binding affinity and efficacy of thyroid hormone receptor ligands using QSAR and structure-based modeling methods. *Toxicol Appl Pharmacol* 280(1):177–189, PMID: 25058446, <https://doi.org/10.1016/j.taap.2014.07.009>.
- Porreca I, Ulloa Severino L, D'Angelo F, Cuomo D, Ceccarelli M, Altucci L, et al. 2016. "Stockpile" of slight transcriptomic changes determines the indirect genotoxicity of low-dose BPA in thyroid cells. *PLoS One* 11(3):e0151618, PMID: 26982218, <https://doi.org/10.1371/journal.pone.0151618>.
- Porterfield SP, Hendrich CE. 1993. The role of thyroid hormones in prenatal and neonatal neurological development—current perspectives. *Endocr Rev* 14(1):94–106, PMID: 8491157, <https://doi.org/10.1210/edrv.14-1-94>.
- Power DM, Elias NP, Richardson SJ, Mendes J, Soares CM, Santos C. 2000. Evolution of the thyroid hormone-binding protein, transthyretin. *Gen Comp Endocrinol* 119(3):241–255, PMID: 11017772, <https://doi.org/10.1006/gcen.2000.7520>.
- Power DM, Llewellyn L, Faustino M, Nowell MA, Björnsson BT, Einarsdottir IE, et al. 2001. Thyroid hormones in growth and development of fish. *Comp Biochem Physiol C Toxicol Pharmacol* 130(4):447–459, PMID: 11738632, [https://doi.org/10.1016/S1532-0456\(01\)00271-X](https://doi.org/10.1016/S1532-0456(01)00271-X).
- Ramadoss P, Abraham BJ, Tsai L, Zhou Y, Costa-e-Sousa RH, Ye F, et al. 2014. Novel mechanism of positive *versus* negative regulation by thyroid hormone receptor β1 (TRβ1) identified by genome-wide profiling of binding sites in mouse liver. *J Biol Chem* 289(3):1313–1328, PMID: 24288132, <https://doi.org/10.1074/jbc.M113.521450>.
- Ren XM, Guo LH. 2012. Assessment of the binding of hydroxylated polybrominated diphenyl ethers to thyroid hormone transport proteins using a site-specific fluorescence probe. *Environ Sci Technol* 46(8):4633–4640, PMID: 22482873, <https://doi.org/10.1021/es2046074>.
- Renko K, Hoefig CS, Hiller F, Schomburg L, Köhrle J. 2012. Identification of iopanoic acid as substrate of type 1 deiodinase by a novel nonradioactive iodide-release assay. *Endocrinology* 153(5):2506–2513, PMID: 22434082, <https://doi.org/10.1210/en.2011-1863>.
- Renko K, Schäche S, Hoefig CS, Welsink T, Schwiebert C, Braun D, et al. 2015. An improved nonradioactive screening method identifies genistein and xanthohumol as potent inhibitors of iodothyronine deiodinases. *Thyroid* 25(8):962–968, PMID: 25962824, <https://doi.org/10.1089/thy.2015.0058>.
- Richard S, Flamant F. 2018. Regulation of T3 availability in the developing brain: the mouse genetics contribution. *Front Endocrinol (Lausanne)* 9:265, PMID: 29892264, <https://doi.org/10.3389/fendo.2018.00265>.
- Richards JB, Ingbar SH. 1959. Effects of propylthiouracil and perchlorate on the biogenesis of thyroid hormone. *Endocrinology* 65(2):198–207, PMID: 13672142, <https://doi.org/10.1210/endo-65-2-198>.
- Richardson VM, Staskal DF, Ross DG, Diliberto JJ, DeVito MJ, Birnbaum LS. 2008. Possible mechanisms of thyroid hormone disruption in mice by BDE 47, a major polybrominated diphenyl ether congener. *Toxicol Appl Pharmacol* 226(3):244–250, PMID: 17964624, <https://doi.org/10.1016/j.taap.2007.09.015>.
- Richardson SJ, Van Herck S, Delbaere J, McAllan BM, Darras VM. 2018. The affinity of transthyretin for T₃ or T₄ does not determine which form of the hormone accumulates in the choroid plexus. *Gen Comp Endocrinol* 264:131–137, PMID: 28919452, <https://doi.org/10.1016/j.ygcen.2017.09.012>.
- Roberts LM, Woodford K, Zhou M, Black DS, Haggerty JE, Tate EH, et al. 2008. Expression of the thyroid hormone transporters monocarboxylate transporter-8 (*SLC16A2*) and organic ion transporter-14 (*SLCO1C1*) at the blood-brain barrier. *Endocrinology* 149(12):6251–6261, PMID: 18687783, <https://doi.org/10.1210/en.2008-0378>.
- Romanov S, Medvedev A, Gambarian M, Poltoratskaya N, Moeser M, Medvedeva L, et al. 2008. Homogeneous reporter system enables quantitative functional assessment of multiple transcription factors. *Nat Methods* 5(3):253–260, PMID: 18297081, <https://doi.org/10.1038/nmeth.1186>.
- Rooney AA, Boyles AL, Wolfe MS, Bucher JR, Thayer KA. 2014. Systematic review and evidence integration for literature-based environmental health science assessments. *Environ Health Perspect* 122(7):711–718, PMID: 24755067, <https://doi.org/10.1289/ehp.1307972>.
- Rootwelt K, Ganes T, Johannessen SI. 1978. Effect of carbamazepine, phenytoin and phenobarbitone on serum levels of thyroid hormones and thyrotropin in humans. *Scand J Clin Lab Invest* 38(8):731–736, PMID: 105401, <https://doi.org/10.3109/00365517809104880>.
- Rosebrough RW, Russell BA, McMurtry JP. 2006. Studies on doses of methimazole (MMI) and its administration regimen on broiler metabolism. *Comp Biochem Physiol Part A Mol Integr Physiol* 143(1):35–41, PMID: 16337159, <https://doi.org/10.1016/j.cbpa.2005.10.019>.
- Rosenberg SA, Watt ED, Judson RS, Simmons SO, Paul Friedman K, Dybdahl M, et al. 2017. QSAR models for thyroperoxidase inhibition and screening of U.S. and EU chemical inventories. *Comput Toxicol* 4:11–21, <https://doi.org/10.1016/j.comtox.2017.07.006>.
- Rosenfeld JM, Vargas R Jr, Xie W, Evans RM. 2003. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. *Mol Endocrinol* 17(7):1268–1282, PMID: 12663745, <https://doi.org/10.1210/me.2002-0421>.
- Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, et al. 2010. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. *J Toxicol Environ Health B Crit Rev* 13(2–4):329–346, PMID: 20574906, <https://doi.org/10.1089/10937404.2010.483949>.
- Royland JE, Parker JS, Gilbert ME. 2008. A genomic analysis of subclinical hypothyroidism in hippocampus and neocortex of the developing rat brain. *J Neuroendocrinol* 20(12):1319–1338, PMID: 19094080, <https://doi.org/10.1111/j.1365-2826.2008.01793.x>.
- Sakane Y, Iida M, Hasebe T, Fujii S, Buchholz DR, Ishizuya-Oka A, et al. 2018. Functional analysis of thyroid hormone receptor beta in *Xenopus tropicalis* founders using CRISPR-Cas. *Biol Open* 7(1):bio030338, PMID: 29358165, <https://doi.org/10.1242/bio.030338>.
- Salvatore D, Tu H, Harney JW, Larsen PR. 1996. Type 2 iodothyronine deiodinase is highly expressed in human thyroid. *J Clin Invest* 98(4):962–968, PMID: 8770868, <https://doi.org/10.1172/JCI118880>.
- Santini F, Vitti P, Ceccarini G, Mammoli C, Rosellini V, Pelosini C, et al. 2003. *In vitro* assay of thyroid disruptors affecting TSH-stimulated adenylate cyclase activity. *J Endocrinol Invest* 26(10):950–955, PMID: 14759065, <https://doi.org/10.1007/BF03348190>.
- Savu L, Vranckx R, Rouaze-Romet M, Maya M, Nunez EA, Tréton J, et al. 1991. A senescence up-regulated protein: the rat thyroxine-binding globulin (TBG). *Biochim Biophys Acta* 1097(1):19–22, PMID: 1907201, [https://doi.org/10.1016/0925-4439\(91\)90017-4](https://doi.org/10.1016/0925-4439(91)90017-4).
- Scanlan TS. 2009. Minireview: 3-iodothyronamine (T₃AM): a new player on the thyroid endocrine team? *Endocrinology* 150(3):1108–1111, PMID: 19116337, <https://doi.org/10.1210/en.2008-1596>.
- Schneider MJ, Fiering SN, Pallud SE, Parlow AF, St Germain DL, Galton VA. 2001. Targeted disruption of the type 2 selenodeiodinase gene (*DIO2*) results in a phenotype of pituitary resistance to T₄. *Mol Endocrinol* 15(12):2137–2148, PMID: 11731615, <https://doi.org/10.1210/mend.15.12.0740>.
- Schneider MJ, Fiering SN, Thai B, Wu SY, St Germain E, Parlow AF, et al. 2006. Targeted disruption of the type 1 selenodeiodinase gene (*Dio1*) results in marked changes in thyroid hormone economy in mice. *Endocrinology* 147(1):580–589, PMID: 16223863, <https://doi.org/10.1210/en.2005-0739>.
- Schreiber G, Aldred AR, Jaworowski A, Nilsson C, Achen MG, Segal MB. 1990. Thyroxine transport from blood to brain via transthyretin synthesis in choroid-plexus. *Am J Physiol* 258(2 Pt 2):R338–R345, PMID: 2309926, <https://doi.org/10.1152/ajpregu.1990.258.2.R338>.
- Schrinks M, Vrabie CM, Gutleb AC, Faassen EJ, Rietjens I, Murk AJ. 2006. T-screen to quantify functional potentiating, antagonistic and thyroid hormone-like activities of poly halogenated aromatic hydrocarbons (PHAHs). *Toxicol In Vitro* 20(4):490–498, PMID: 16219445, <https://doi.org/10.1016/j.tiv.2005.09.001>.

- Schuur AG, Legger FF, van Meeteren ME, Moonen MJH, van Leeuwen-Bol I, Bergman Å, et al. 1998. In vitro inhibition of thyroid hormone sulfation by hydroxylated metabolites of halogenated aromatic hydrocarbons. *Chem Res Toxicol* 11(9):1075–1081, PMID: 9760282, <https://doi.org/10.1021/tx800046>.
- Serrano J, Higgins L, Withuhn BA, Anderson LB, Markowski T, Holcombe GW, et al. 2010. *In vivo* assessment and potential diagnosis of xenobiotics that perturb the thyroid pathway: proteomic analysis of *Xenopus laevis* brain tissue following exposure to model T4 inhibitors. *Comp Biochem Physiol Part D Genomics Proteomics* 5(2):138–150, PMID: 20452843, <https://doi.org/10.1016/j.cbd.2010.03.007>.
- Sharlin DS, Ng L, Verrey F, Visser TJ, Liu Y, Olszewski RT, et al. 2018. Deafness and loss of cochlear hair cells in the absence of thyroid hormone transporters Slc16a2 (Mct8) and Slc16a10 (Mct10). *Sci Rep* 8(1):4403, PMID: 29535325, <https://doi.org/10.1038/s41598-018-22553-w>.
- Sher ES, Xu XM, Adams PM, Craft CM, Stein SA. 1998. The effects of thyroid hormone level and action in developing brain: are these targets for the actions of polychlorinated biphenyls and dioxins? *Toxicol Ind Health* 14(1–2):121–158, PMID: 9460173, <https://doi.org/10.1177/074823379801400110>.
- Shimizu R, Yamaguchi M, Uramaru N, Kuroki H, Ohta S, Kitamura S, et al. 2013. Structure–activity relationships of 44 halogenated compounds for iodothyrosine deiodinase-inhibitory activity. *Toxicology* 314(1):22–29, PMID: 24012475, <https://doi.org/10.1016/j.tox.2013.08.017>.
- Shobair M, Nelms M, Deisenroth C, Patlewicz G, Paul Friedman K. 2019. A high-throughput approach to identify and prioritize putative thyroid-stimulating hormone receptor agonists and antagonists [Abstract #3154/P73]. In: *SOT Annual Meeting*, 10–14 March 2019, Baltimore, Maryland: Society of Toxicology.
- Silva JE. 1995. Thyroid hormone control of thermogenesis and energy balance. *Thyroid* 5(6):481–492, PMID: 8808101, <https://doi.org/10.1089/thy.1995.5.481>.
- Sipes NS, Martin MT, Kothiyal P, Reif DM, Judson RS, Richard AM, et al. 2013. Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling Assays. *Chem Res Toxicol* 26(6):878–895, PMID: 23611293, <https://doi.org/10.1021/tx40021f>.
- Skeaff SA. 2011. Iodine deficiency in pregnancy: the effect on neurodevelopment in the child. *Nutrients* 3(2):265–273, PMID: 2254096, <https://doi.org/10.3390/nu3020265>.
- Song Y, Miao JJ, Pan LQ, Wang X. 2016. Exposure to 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) alters thyroid hormone levels and thyroid hormone-regulated gene transcription in manila clam *Ruditapes philippinarum*. *Chemosphere* 152:10–16, PMID: 26943874, <https://doi.org/10.1016/j.chemosphere.2016.02.049>.
- Springer C, Dere E, Hall SJ, McDonnell EV, Roberts SC, Butt CM, et al. 2012. Rodent thyroid, liver, and fetal testis toxicity of the monoester metabolite of bis-(2-ethylhexyl) tetrabromophthalate (TBPH), a novel brominated flame retardant present in indoor dust. *Environ Health Perspect* 120(12):1711–1719, PMID: 23014847, <https://doi.org/10.1289/ehp.1204932>.
- St Germain DL, Schwartzman RA, Croteau W, Kanamori A, Wang Z, Brown DD, et al. 1994. A thyroid hormone-regulated gene in *Xenopus laevis* encodes a type III iodothyronine 5-deiodinase. *Proc Natl Acad Sci U S A* 91(16):7767–7771, PMID: 8052658, <https://doi.org/10.1073/pnas.91.16.7767>.
- Steinmaus C, Pearl M, Kharrazi M, Blount BC, Miller MD, Pearce EN, et al. 2016. Thyroid hormones and moderate exposure to perchlorate during pregnancy in women in Southern California. *Environ Health Perspect* 124(6):861–867, PMID: 26485730, <https://doi.org/10.1289/ehp.1409614>.
- Stinckens E, Vergauwen L, Schroeder AL, Maho W, Blackwell BR, Witters H, et al. 2016. Impaired anterior swim bladder inflation following exposure to the thyroid peroxidase inhibitor 2-mercaptopbenzothiazole part II: zebrafish. *Aquat Toxicol* 173:204–217, PMID: 26818709, <https://doi.org/10.1016/j.aquatox.2015.12.023>.
- Stohn JP, Martinez ME, Hernandez A. 2016. Decreased anxiety- and depression-like behaviors and hyperactivity in a type 3 deiodinase-deficient mouse showing brain thyrotoxicosis and peripheral hypothyroidism. *Psychoneuroendocrinology* 74:46–56, PMID: 27580013, <https://doi.org/10.1016/j.psyneuen.2016.08.021>.
- Sun H, Shen OX, Wang XR, Zhou L, Zhen SQ, Chen XD. 2009. Anti-thyroid hormone activity of bisphenol A, tetrabromobisphenol A and tetrachlorobisphenol A in an improved reporter gene assay. *Toxicol In Vitro* 23(5):950–954, PMID: 19457453, <https://doi.org/10.1016/j.tiv.2009.05.004>.
- Szabo DT, Richardson VM, Ross DG, Diliberto JJ, Kodavanti PRS, Birnbaum LS. 2009. Effects of perinatal PBDE exposure on hepatic phase I, phase II, phase III, and deiodinase 1 gene expression involved in thyroid hormone metabolism in male rat pups. *Toxicol Sci* 107(1):27–39, PMID: 18978342, <https://doi.org/10.1093/toxsci/kfn230>.
- Thomas RS, Paules RS, Simeonov A, Fitzpatrick SC, Crofton KM, Casey WM, et al. 2018. The US Federal Tox21 Program: a strategic and operational plan for continued leadership. *ALTEX* 35(2):163–168, PMID: 29529324, <https://doi.org/10.1457/altex.1803011>.
- Thomas RS, Philbert MA, Auerbach SS, Wetmore BA, Devito MJ, Cote I, et al. 2013a. Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. *Toxicol Sci* 136(1):4–18, PMID: 23958734, <https://doi.org/10.1093/toxsci/kft178>.
- Thomas RS, Wesselkamper SC, Wang NC, Zhao QJ, Petersen DD, Lambert JC, et al. 2013b. Temporal concordance between apical and transcriptional points of departure for chemical risk assessment. *Toxicol Sci* 134(1):180–194, PMID: 23596260, <https://doi.org/10.1093/toxsci/kft094>.
- Tietge JE, Butterworth BC, Haselman JT, Holcombe GW, Hornung MW, Korte JJ, et al. 2010. Early temporal effects of three thyroid hormone synthesis inhibitors in *Xenopus laevis*. *Aquat Toxicol* 98(1):44–50, PMID: 20153061, <https://doi.org/10.1016/j.aquatox.2010.01.014>.
- Tietge JE, Degitz SJ, Haselman JT, Butterworth BC, Korte JJ, Kosian PA, et al. 2013. Inhibition of the thyroid hormone pathway in *Xenopus laevis* by 2-mercaptopbenzothiazole. *Aquat Toxicol* 126:128–136, PMID: 23178179, <https://doi.org/10.1016/j.aquatox.2012.10.013>.
- Tietge JE, Holcombe GW, Flynn KM, Kosian PA, Korte JJ, Anderson LE, et al. 2005. Metamorphosis inhibition of *Xenopus laevis* by sodium perchlorate: effects on development and thyroid histology. *Environ Toxicol Chem* 24(4):926–933, PMID: 15839568, <https://doi.org/10.1002/etc.105.1>.
- Titus S, Neumann S, Zheng W, Southall N, Michael S, Klumpp C, et al. 2008. Quantitative high-throughput screening using a live-cell cAMP assay identifies small-molecule agonists of the TSH receptor. *J Biomol Screen* 13(2):120–127, PMID: 18216391, <https://doi.org/10.1177/1087057107313786>.
- Trubiroha A, Gillotay P, Giusti N, Gacquer D, Libert F, Lefort A, et al. 2018. A rapid CRISPR/Cas-based mutagenesis assay in zebrafish for identification of genes involved in thyroid morphogenesis and function. *Sci Rep* 8(1):5647, PMID: 29618800, <https://doi.org/10.1038/s41598-018-24036-4>.
- U.S. EPA (U.S. Environmental Protection Agency). 1998a. *Health Effects Test Guidelines: OPPTS 870.3100 90-Day Oral Toxicity in Rodents*. EPA 712-C-98–199. Washington DC: U.S. EPA. <https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0010> [accessed 15 September 2018].
- U.S. EPA. 1998b. *Health Effects Test Guidelines: OPPTS 870.3700 Prenatal Developmental Toxicity Study*. EPA 712-C-98–207. Washington DC: U.S. EPA. <https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0017> [accessed 15 September 2018].
- U.S. EPA. 1998c. *Health Effects Test Guidelines: OPPTS 870.6300 Developmental Neurotoxicity Study*. EPA 712-C-98–239. Washington DC: U.S. EPA. <https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0042> [accessed 15 September 2018].
- U.S. EPA. 1998d. *Series 870—Health Effects Test Guidelines, Group C, Chronic Toxicity Test Guidelines*. Washington DC: U.S. EPA. <https://www.epa.gov/test-guidelines-pesticides-and-toxic-substances/series-870-health-effects-test-guidelines> [accessed 15 September 2018].
- U.S. EPA. 2000a. *Health Effects Test Guidelines: OPPTS 870.3050 Repeated Dose 28-Day Oral Toxicity Study in Rodents*. EPA 712-C-00–366. Washington DC: U.S. EPA. <https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0009> [accessed 15 September 2018].
- U.S. EPA. 2000b. *Health Effects Test Guidelines: OPPTS 870.3650 Combined Repeated Dose Toxicity with the Reproduction/Developmental Toxicity Screening Test*. EPA 712-C-00–368. Washington DC: U.S. EPA. <https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0156-0016> [accessed 15 September 2018].
- U.S. EPA. 2005. *Guidance for Thyroid Assays in Pregnant Animals, Fetuses and Postnatal Animals, and Adult Animals*. Washington DC: U.S. EPA, Office of Chemical Safety and Pollution Prevention, Office of Pesticide Programs. <https://www.epa.gov/pesticide-registration/guidance-thyroid-assays-pregnant-animals-fetuses-and-postnatal-animals-and> [accessed 10 June 2016].
- U.S. EPA. 2009. *Series 890—Endocrine Disruptor Screening Program Test Guidelines*. Washington DC: U.S. EPA, Endocrine Disruptor Screening Program. <https://www.epa.gov/test-guidelines-pesticides-and-toxic-substances/series-890-endocrine-disruptor-screening-program> [accessed 1 May 2016].
- U.S. EPA. 2014. *Integrated Bioactivity and Exposure Ranking: A Computational Approach for the Prioritization and Screening of Chemicals in the Endocrine Disruptor Screening Program*. EPA-HQ-OPP-2014-0614-0003. Washington DC: U.S. EPA. <https://www.regulations.gov/document?D=EPA-HQ-OPP-2014-0614-0003> [accessed 1 June 2016].
- U.S. EPA. 2015a. ToxCast and Tox21 Summary Files from invitrodb_v2. October 2015 data release. <http://www2.epa.gov/chemical-research/toxicity-forecaster-toxcasttm-data> [accessed 2 January 2016].
- U.S. EPA. 2015b. Use of high throughput assays and computational tools: endocrine disruptor screening program; notice of availability and opportunity for comment. *Fed Reg* 80:118 (19 June 2015). <https://www.federalregister.gov/articles/2015/06/19/2015-15182/use-of-high-throughput-assays-and-computational-tools-endocrine-disruptor-screening-program-notice> [accessed 7 March 2016].
- U.S. EPA. 2017. *Continuing Development of Alternative High-Throughput Screens to Determine Endocrine Disruption, Focusing on Androgen Receptor, Steroidogenesis, and Thyroid Pathways*. Washington DC: U.S. EPA, Endocrine Disruptor Screening Program. https://www.epa.gov/sites/production/files/2017-09/documents/2017_edsp_white_paper_public.pdf [accessed 15 January 2018].
- U.S. EPA. 2018. *Assessing and Managing Chemicals under TSCA; Alternative Test Methods and Strategies to Reduce Vertebrate Animal Testing*. Washington DC:

- U.S. EPA. <https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/alternative-test-methods-and-strategies-reduce> [accessed 5 August 2018].
- van Raalte DH, Li M, Pritchard PH, Wasan KM. 2004. Peroxisome proliferator-activated receptor (PPAR)- α : a pharmacological target with a promising future. *Pharm Res* 21(9):1531–1538, PMID: 15497675, <https://doi.org/10.1023/b:pham.0000041444.06122.8d>.
- Vansell NR, Klaassen CD. 2002. Effect of microsomal enzyme inducers on the biliary excretion of triiodothyronine (T_3) and its metabolites. *Toxicol Sci* 65(2):184–191, PMID: 11812922, <https://doi.org/10.1093/toxsci/65.2.184>.
- Vermiglio F, Lo Presti VP, Moleti M, Sidoti M, Tortorella G, Scaffidi G, et al. 2004. Attention deficit and hyperactivity disorders in the offspring of mothers exposed to mild-moderate iodine deficiency: a possible novel iodine deficiency disorder in developed countries. *J Clin Endocrinol Metab* 89(12):6054–6060, PMID: 15579758, <https://doi.org/10.1210/jc.2004-0571>.
- Villeneuve DL, Angrish MM, Fortin MC, Katsiadaki I, Leonard M, Margiotta-Casaluci L, et al. 2018. Adverse outcome pathway networks II: network analytics. *Environ Toxicol Chem* 37(6):1734–1748, PMID: 29492998, <https://doi.org/10.1002/etc.4124>.
- Villeneuve DL, Crump D, Garcia-Reyero N, Hecker M, Hutchinson TH, LaLone CA, et al. 2014. Adverse outcome pathway (AOP) development I: strategies and principles. *Toxicol Sci* 142(2):312–320, PMID: 25466378, <https://doi.org/10.1093/toxsci/kfu199>.
- Villeneuve DL, Garcia-Reyero N, Martinović-Weigelt D, Li ZH, Watanabe KH, Orlando EF, et al. 2012. A graphical systems model and tissue-specific functional gene sets to aid transcriptomic analysis of chemical impacts on the female teleost reproductive axis. *Mutat Res* 746(2):151–162, PMID: 22227403, <https://doi.org/10.1016/j.mrgentox.2011.12.016>.
- Visser WE, Friesema ECH, Visser TJ. 2011. Thyroid hormone transporters: the knowns and the unknowns. *Mol Endocrinol* 25(1):1–14, PMID: 20660303, <https://doi.org/10.1210/me.2010-0095>.
- Visser TJ, Kaptein E, van Toor H, van Raaij JA, van den Berg KJ, Joe CT, et al. 1993. Glucuronidation of thyroid-hormone in rat liver: effects of in vivo treatment with microsomal enzyme inducers and in vitro assay conditions. *Endocrinology* 133(5):2177–2186, PMID: 8404669, <https://doi.org/10.1210/endo.133.5.8404669>.
- Wang RL, Biales AD, Garcia-Reyero N, Perkins EJ, Villeneuve DL, Ankley GT, et al. 2016. Fish connectivity mapping: linking chemical stressors by their mechanisms of action-driven transcriptomic profiles. *BMC Genomics* 17:84, PMID: 26822894, <https://doi.org/10.1186/s12864-016-2406-y>.
- Wang J, Hallinger DR, Murr AS, Buckalew AR, Simmons SO, Laws SC, et al. 2018. High-throughput screening and quantitative chemical ranking for sodium-iodide symporter inhibitors in ToxCast phase I chemical library. *Environ Sci Technol* 52(9):5417–5426, PMID: 29611697, <https://doi.org/10.1021/acs.est.7b06145>.
- Wang LO, James MO. 2006. Inhibition of sulfotransferases by xenobiotics. *Curr Drug Metab* 7(1):83–104, PMID: 16454694, <https://doi.org/10.2174/13892000674832596>.
- Weiss JM, Andersson PL, Lamoree MH, Leonards PEG, van Leeuwen SPJ, Hamers T. 2009. Competitive binding of poly- and perfluorinated compounds to the thyroid hormone transport protein transthyretin. *Toxicol Sci* 109(2):206–216, PMID: 19293372, <https://doi.org/10.1093/toxsci/kfp055>.
- Westholm DE, Stenehjem DD, Rumbley JN, Drewes LR, Anderson GW. 2009. Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. *Endocrinology* 150(2):1025–1032, PMID: 18845642, <https://doi.org/10.1210/en.2008-0188>.
- White SS, Fenton SE, Hines EP. 2011. Endocrine disrupting properties of perfluoroctanoic acid. *J Steroid Biochem Mol Biol* 127(1–2):16–26, PMID: 21397692, <https://doi.org/10.1016/j.jsbmb.2011.03.011>.
- Williams GR. 2008. Neurodevelopmental and neurophysiological actions of thyroid hormone. *J Neuroendocrinol* 20(6):784–794, PMID: 18601701, <https://doi.org/10.1111/j.1365-2826.2008.01733.x>.
- Williams KE, Lemieux GA, Hassis ME, Olshen AB, Fisher SJ, Werb Z. 2016. Quantitative proteomic analyses of mammary organoids reveals distinct signatures after exposure to environmental chemicals. *Proc Natl Acad Sci U S A* 113(10):E1343–E1351, PMID: 26903627, <https://doi.org/10.1073/pnas.1600645113>.
- Wittwehr C, Aladjov H, Ankley G, Byrne HJ, de Knecht J, Heinzle E, et al. 2017. How adverse outcome pathways can aid the development and use of computational prediction models for regulatory toxicology. *Toxicol Sci* 155(2):326–336, PMID: 27994170, <https://doi.org/10.1093/toxsci/kfw207>.
- Wolff J. 1998. Perchlorate and the thyroid gland. *Pharmacol Rev* 50(1):89–105, PMID: 9549759.
- Wong H, Lehman-McKeeman LD, Grubb MF, Grossman SJ, Bhaskaran VM, Solon EG, et al. 2005. Increased hepatobiliary clearance of unconjugated thyroxine determines DMP 904-induced alterations in thyroid hormone homeostasis in rats. *Toxicol Sci* 84(2):232–242, PMID: 15673846, <https://doi.org/10.1093/toxsci/kfi094>.
- Wu YF, Beland FA, Fang JL. 2016. Effect of tricosan, triclocarban, 2,2',4,4'-tetrabromodiphenyl ether, and bisphenol A on the iodide uptake, thyroid peroxidase activity, and expression of genes involved in thyroid hormone synthesis. *Toxicol In Vitro* 32:310–319, PMID: 26827900, <https://doi.org/10.1016/j.tiv.2016.01.014>.
- Wu SY, Green WL, Huang WS, Hays MT, Chopra IJ. 2005. Alternate pathways of thyroid hormone metabolism. *Thyroid* 15(8):943–958, PMID: 16131336, <https://doi.org/10.1089/thy.2005.15.943>.
- Yang J, Yi N, Zhang J, He W, He D, Wu W, et al. 2018. Generation and characterization of a hypothyroidism rat model with truncated thyroid stimulating hormone receptor. *Sci Rep* 8(1):4004, PMID: 29507327, <https://doi.org/10.1038/s41598-018-22405-7>.
- Yen PM. 2001. Physiological and molecular basis of thyroid hormone action. *Physiol Rev* 81(3):1097–1142, PMID: 11427693, <https://doi.org/10.1152/physrev.2001.81.3.1097>.
- Yeo PP, Bates D, Howe JG, Ratcliffe WA, Schardt CW, Heath A, et al. 1978. Anticonvulsants and thyroid function. *Br Med J* 1(6127):1581–1583, PMID: 656820, <https://doi.org/10.1136/bmj.1.6127.1581>.
- York RG, Barnett J Jr, Brown WR, Garman RH, Mattie DR, Dodd D. 2004. A rat neurodevelopmental evaluation of offspring, including evaluation of adult and neonatal thyroid, from mothers treated with ammonium perchlorate in drinking water. *Int J Toxicol* 23(3):191–214, PMID: 15204722, <https://doi.org/10.1080/10915810490475835>.
- You SH, Gauger KJ, Bansal R, Zoeller RT. 2006. 4-hydroxy-PCB106 acts as a direct thyroid hormone receptor agonist in rat GH3 cells. *Mol Cell Endocrinol* 257–258:26–34, PMID: 16930818, <https://doi.org/10.1016/j.mce.2006.06.009>.
- Young RA, Meyers B, Alex S, Fang SL, Braverman LE. 1988. Thyroxine binding to serum thyronine-binding globulin in thyroidectomized adult and normal neonatal rats. *Endocrinology* 122(5):2318–2323, PMID: 3129285, <https://doi.org/10.1210/endo-122-5-2318>.
- Yu WG, Liu W, Jin YH. 2009. Effects of perfluorooctane sulfonate on rat thyroid hormone biosynthesis and metabolism. *Environ Toxicol Chem* 28(5):990–996, PMID: 19045937, <https://doi.org/10.1897/08-345.1>.
- Zhang JS, Lazar MA. 2000. The mechanism of action of thyroid hormones. *Annu Rev Physiol* 62:439–466, PMID: 10845098, <https://doi.org/10.1146/annurev.physiol.62.1.439>.
- Zhang Y-X, Shen C-H, Lai Q-L, Fang G-L, Ming W-J, Lu R-Y, et al. 2016. Effects of antiepileptic drug on thyroid hormones in patients with epilepsy: a meta-analysis. *Seizure* 35:72–79, PMID: 26803280, <https://doi.org/10.1016/j.seizure.2016.01.010>.
- Zhou T, Taylor MM, DeVito MJ, Crofton KA. 2002. Developmental exposure to brominated diphenyl ethers results in thyroid hormone disruption. *Toxicol Sci* 66(1):105–116, PMID: 11861977, <https://doi.org/10.1093/toxsci/66.1.105>.
- Zoeller RT. 2005. Environmental chemicals as thyroid hormone analogues: new studies indicate that thyroid hormone receptors are targets of industrial chemicals. *Mol Cell Endocrinol* 242(1–2):10–15, PMID: 16150534, <https://doi.org/10.1016/j.mce.2005.07.006>.
- Zoeller RT. 2010. New insights into thyroid hormone action in the developing brain: the importance of T_3 degradation. *Endocrinology* 151(11):5089–5091, PMID: 20962056, <https://doi.org/10.1210/en.2010-0926>.
- Zoeller RT, Bansal R, Parris C. 2005. Bisphenol-A, an environmental contaminant that acts as a thyroid hormone receptor antagonist *in vitro*, increases serum thyroxine, and alters RC3/neurogranin expression in the developing rat brain. *Endocrinology* 146(2):607–612, PMID: 15498886, <https://doi.org/10.1210/en.2004-1018>.
- Zoeller RT, Crofton KM. 2005. Mode of action: developmental thyroid hormone insufficiency—neurological abnormalities resulting from exposure to propylthiouracil. *Crit Rev Toxicol* 35(8–9):771–781, PMID: 16417044, <https://doi.org/10.1080/10408440591007313>.
- Zoeller RT, Rovet J. 2004. Timing of thyroid hormone action in the developing brain: clinical observations and experimental findings. *J Neuroendocrinol* 16(10):809–818, PMID: 15500540, <https://doi.org/10.1111/j.1365-2826.2004.01243.x>.